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Down syndrome, caused by trisomy of the 21st chromosome, leads to 
lifelong cognitive impairment, characterized by alterations to neural cells and 
circuits, brain tissue, and behavior. Efforts to understand this disorder first require 
an understanding of the genes encoded on the 21st chromosome. The small 
roundworm, Caenorhabditis elegans, is an excellent model to uncover the in vivo 
function of human 21st chromosome orthologs. 
The first chapter of my dissertation provides background on Down 
syndrome—how it is thought to arise, the phenotypes it causes within the nervous 
system, which genes and pathways may underlie these phenotypes, and a brief 
survey of the established mouse models used to interrogate the disorder. I 
conclude by arguing that the more tractable model organism, C. elegans, can be 
used to complement research with rodents and that worm is a particularly fruitful 
system for initial gene characterization. 
In my next chapter, I discuss two systematic screens I performed on human 
21st chromosome orthologs in worm: the first, a behavioral screen to identify genes 
 vii 
broadly affecting nervous system function; the second, a pharmacological screen 
to identify genes involved in synaptic signaling. In these two screens, I identified 
a handful of candidate genes, several of which had not previously been linked to 
the nervous system in any animal.  
In Chapter 3, I discuss one of these novel candidate genes, mtq-2, that 
emerged from my screen. I provide a fuller characterization of it and show that it 
is required for normal nervous system function, normal excitatory 
neurotransmission, and that it functions, specifically, in cholinergic neurons to 
mediate its effects. I also discuss the potential genetic pathways in which mtq-2 
may work to control synaptic vesicle release in excitatory motor neurons. Here, I 
present evidence that suggests mtq-2 may function upstream of or in conjunction 
with at least one Gα signaling protein, GαO. I conclude by sharing preliminary 
results on overexpression of mtq-2 and suggest future directions for inquiry. 
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CHAPTER ONE 
 
INTRODUCTION 
 
  
 2 
OVERVIEW 
In 1866 a young medical doctor, John Langdon Down, published a brief in 
which he characterized patients with a consistently similar set of traits: cognitive 
impairment, facial dysmorphology, and speech and motor deficits amenable to 
improvement by “systematic training” (Down, 1866). This early system of 
phenotypic classification denotes the start of the field of Down syndrome 
research, though it would take nearly another hundred years and seismic 
advances in biotechnology before a collection of phenotypes could be linked to 
the presence of an extra chromosome. 
Trisomy of the 21st chromosome is the most common type of autosomal 
aneuploidy with long-term viability (Antonarakis, Lyle, Dermitzakis, Reymond, 
& Deutsch, 2004; Gardiner et al., 2010). Children born with Down syndrome 
present with an array of phenotypes  ranging from the superficial—epicanthic 
folds, flat nasal bridges, Brushfield spots—to those that severely affect quality of 
life—intellectual disability, low muscle tone, septal heart defects, and early onset 
Alzheimer disease (Korenberg et al., 1994). Down was a thorough, careful 
observer—the phenotypes he enumerated in the 19th century are still those most 
widely associated with the syndrome bearing his name; yet unraveling how 
complete (or in rarer cases, partial) triplication of the 21st chromosome results in 
Down syndrome remains elusive.  
Of the phenotypes associated with Down syndrome, most have variable 
penetrance with two notable exceptions: cognitive impairment and neonatal 
hypotonia. These phenotypes are inevitable outcomes for patients afflicted with 
the disorder (Korenberg et al., 1994). Hypotonia, or low muscle tone, is 
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characterized by laxity of the ligaments, which hinders normal motor 
development. Though children with Down syndrome are ultimately able to 
reach major motor milestones, they do so at a delayed rate and by relying on 
compensatory strategies to move (Agiovlasitis, McCubbin, Yun, Pavol, & 
Widrick, 2009; Carr, 1970; Melyn & White, 1973; Rigoldi, Galli, Mainardi, 
Crivellini, & Albertini, 2011). Movement is thus, more difficult and more 
energetically taxing for the individual with Down syndrome (Agiovlasitis et al., 
2009).  
The second fully penetrant phenotype, cognitive impairment, causes more 
severe difficulties for Down syndrome patients, their families, and society. Most 
individuals with Down syndrome are moderately to severely intellectually 
disabled, with a median IQ of ~50 (Chapman & Hesketh, 2000; Dierssen, Herault, 
& Estivill, 2009). Though useful as a diagnostic metric, an IQ score cannot—and 
does not—capture the complexity of human behavior. As I will discuss in a later 
section, the cognitive profile of individuals with Down syndrome is distinct from 
other types of intellectual disability and correlates to deficits in specific brain 
regions.  
Of final note, nearly all individuals with Down syndrome develop the 
characteristic pathophysiological hallmarks of Alzheimer’s disease in adulthood. 
Understanding how neurodegeneration arises and progresses in older patients 
with Down syndrome may provide insight into more global mechanisms of 
Alzheimer’s disease in the general population. 
What follows is a survey of Down syndrome—the most common 
hypotheses underlying its cause, its effects on specific areas of the nervous 
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system, and how invertebrate models—C. elegans in particular—can augment our 
understanding of Down syndrome related genes and genetic pathways. Though 
trisomy of the 21st chromosome can affect every major organ system, a discussion 
of the non-neurological phenotypes among people with Down syndrome is 
beyond my scope. 
 
CAUSES OF DOWN SYNDROME 
Historically, two hypotheses were advanced to explain the development 
of Down syndrome due to the presence of a third 21st chromosome—the 
amplified developmental instability hypothesis and the “gene dosage” 
hypothesis (Dierssen, 2012; Pritchard & Kola, 1999). More recent ways of 
thinking—with which I agree—argue for a more nuanced interpretation. I will 
discuss both historical and contemporary arguments here. 
The amplified developmental instability hypothesis posits that the 
phenotypes associated with Down syndrome are the result not of overexpression 
of any specific gene, but rather a generalized disruption of homeostasis triggered 
by an excess of genetic material (Shapiro, 1975). Central to the argument is that 
organisms develop within the context of tight gene dosage parameters. Further, 
the most variable anthropometric traits are also those that are most susceptible to 
environmental influences. Human height, for instance, is a highly variable trait 
that is highly susceptible to environmental effects. An extra chromosome 
disturbs this evolutionarily optimized homeostasis causing the individual to 
become more susceptible to environmental stress. Traits that are already 
vulnerable to environmental stress (e.g. variable traits like height) are those most 
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likely to become perturbed in Down syndrome. This argument largely sprung 
from the observation that different aneuploidies converge on similar traits. While 
this certainly has some element of truth to it—Williams syndrome (a small 
deletion of the 7th chromosome) and Down syndrome both result in heart defects 
and cognitive impairment—there are critical distinctions. Individuals with Down 
syndrome exhibit discrepancies in their working memory profiles, generally 
performing poorly on verbal tasks, less so on visuospatial tasks (Dierssen, 2012). 
However, this pattern is of relative visuospatial dominance is reversed in 
individuals with Williams syndrome, which suggests that alterations to specific 
genes or genomic regions underlie specific patterns of memory impairment 
(Conners, Moore, Loveall, & Merrill, 2011; Vicari, Bellucci, & Carlesimo, 2005). 
The development of early onset Alzheimer’s disease is also unique to 
Down syndrome, but not to other aneuploidies. When Shapiro advanced the 
amplified developmental instability hypothesis in the 1970s, the average life 
expectancy for people with Down syndrome was about 30-35 years old (Deaton, 
1973; Thase, 1982). Individuals with Down syndrome do not display the 
pathological markers of Alzheimer’s—Aβ plaques and neurofibrillary tangles—
until their 40s and do not present with dementia until their 50s, thus obscuring 
the inevitability of developing Alzheimer’s disease to researchers of past 
generations (Hartley et al., 2015).  
The idea of dose sensitive genes encoded on the 21st chromosome has 
often been framed in contrast to the developmental instability hypothesis—an 
unfortunate false dilemma (Pritchard & Kola, 1999). Though the human 21st 
chromosome is the smallest chromosome, it has an average, overall gene density 
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(Hattori et al., 2000). Genes encoding long non-coding RNA (lnc-RNA) are 
enriched relative to other chromosomes, while genes encoding microRNA 
(miRNA) are depleted; the density of pseudogenes and protein-coding genes is 
average (Letourneau & Antonarakis, 2012). Conservative estimates state the 
number of protein coding genes on HSA21 as around 220 (Gupta, Dhanasekaran, 
& Gardiner, 2016; Letourneau & Antonarakis, 2012; Nordquist, Smith, & Pierce, 
2018). 
Determining the function of these genes and understanding how they 
might contribute to Down syndrome is a non-trivial task. It is, therefore, 
understandable that Down syndrome researchers would be motivated to identify 
a minimal susceptibility region or “critical region” for the disorder. In 1989, 
researchers identified two rare individuals with Down syndrome who were only 
partially trisomic for the 21st chromosome. By mapping their 21st chromosomes, 
Rahmani identified a small region shared by both patients, which was dubbed—
perhaps prematurely—the Down syndrome critical region (DSCR) (Rahmani et 
al., 1989). Twenty years later, the Korenberg lab found over 30 individuals with 
Down syndrome whose condition sprung, again, from rare partial trisomies of 
the 21st chromosome. Using fine resolution mapping techniques, they discovered 
that there was no single region of conservation among all of the Down syndrome 
patients (Korbel et al., 2009). In other words, no one chromosomal region along 
the 21st chromosome was sufficient to explain all—or even most—of the 
phenotypes associated with Down syndrome (Korbel et al., 2009). Importantly, 
the Korenberg group identified multiple regions that correlated to intellectual 
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disability in Down syndrome, which argues against the involvement of a single 
critical region causative for cognitive impairment.  
Studies using mouse models to investigate the Down syndrome critical 
region have also been conflicted. In mouse, genes orthologous to those on the 
human 21st chromosome are distributed along the 16th, 17th, and 10th 
chromosomes. The purported Down syndrome critical region lies within the 
mouse 16th chromosome. In 2004, the Reeves group created two very useful 
mouse models to investigate the function of the critical region: Ms1Rhr/Ts65Dn 
and Ts1Rhr (Figure 1.1) (Olson, Richtsmeier, Leszl, & Reeves, 2004). In 
Ms1Rhr/Ts65Dn, a mouse segmentally monosomic for the DSCR (Ms1Rhr) was 
crossed to Ts65Dn, a previously established mouse model of Down syndrome. 
Selected Ms1Rhr/Ts65Dn progeny were, thus, disomic for genes within the 
critical region. In contrast, the Ts1Rhr mouse was trisomic only for the DSCR. 
Olson and Reeves examined craniofacial skeletal abnormalities—a hallmark of 
human Down syndrome and the mouse models of it—and found that 
Ms1Rhr/Ts65Dn mice had craniofacial dysmorphology similar to Ts65Dn mice, 
arguing against the necessity of the DSCR. Ts1Rhr mice, which were trisomic 
only for the DSCR, more closely resembled their euploid littermates, arguing 
against the sufficiency of the DSCR. The results of this study indicate that 
overexpression of genes outside of the DSCR contribute to facial phenotypes in 
Down syndrome and that overexpression of the DSCR alone is not sufficient to 
cause these facial phenotypes.  
In a subsequent study, Olson and Reeves examined hippocampal 
behaviors and cell physiology of both the Ts1Rhr and Ms1Rhr/Ts65Dn mice 
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(Olson et al., 2007). They found no differences between euploid and Ts1Rhr mice 
on performance of the Morris water maze, a measure of hippocampal function; 
nor did they find any differences in evoked hippocampal long-term potentiation, 
a measure of synaptic plasticity. However, “subtraction” of the DSCR region in 
the Ms1Rhr/Ts65Dn mice led to behavioral improvements on hippocampal-
dependent tasks. Collectively, these results argue for the necessity of some genes 
or genomic elements in the DSCR region for hippocampal development and 
function, but not its sufficiency. 
Belichenko and Mobley also used Ts1Rhr mice to examine the sufficiency 
of the DSCR to cause both cellular and behavioral deficits (N. P. Belichenko et al., 
2009). The Mobley group found that Ts1Rhr mice had altered hippocampal 
synaptic plasticity and deficits on several other hippocampal-dependent 
behaviors. Notably, the Mobley group and the Reeves examined different 
behaviors and recorded cell responses from different regions of the 
hippocampus, which explains—in part—their differing conclusions.  
Strictly speaking, for the idea of a single DSCR to be true, patients lacking 
this region should not display a majority of Down syndrome phenotypes. This 
assertion is unsupported (Korbel et al., 2009; Lyle et al., 2009). Of course genes 
within this region contribute to the cognitive phenotypes in Down syndrome, 
but there are other regions of susceptibility in both humans (Korbel et al., 2009; 
Lyle et al., 2009) and mouse models (Zhang et al., 2014). I am inclined to agree 
with the sentiments of Gupta and Gardiner that the continued use of the term 
“Down syndrome critical region” is misleading and should be avoided (Gupta et 
al., 2016).  
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How best, then, to consider Down syndrome? Antonarakis proposed a 
sensible model (Antonarakis et al., 2004), which acknowledges the following 
points: 1) there exist dose-sensitive genes or non-genic sequences on the 21st 
chromosome; 2) the ability of these dose-sensitive genes or regions to contribute 
to Down syndrome phenotypes may either be allele-specific on non-specific; 3) 
dose-sensitive elements on the 21st chromosome may interact with, and 
dysregulate, non-21st chromosome genes.  
 
MOLECULAR MECHANISMS OF DOWN SYNDROME 
Cognitive impairment in Down syndrome is rooted in alterations to 
nervous system tissues, cells, and circuits. Though the cause of Down syndrome 
is complex, several genes and pathways have been linked to specific neurological 
phenotypes in Down syndrome. Here I discuss several key studies that provide 
possible molecular mechanisms for the emergence of specific Down syndrome 
phenotypes. Understanding how a supernumerary chromosome causes a 
disorder as varied and complex as Down syndrome is—admittedly—a daunting, 
but worthwhile endeavor. By considering the neurological phenotypes of Down 
syndrome as discrete parts, we can learn about specific genes and pathways—
their contribution to the disease state—and armed with this knowledge, propose 
rational therapies. 
 
Neurodevelopment 
Differences between a euploid and Down syndrome brain become evident 
during embryonic neurodevelopment. Specifically, Down syndrome affected 
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brains are reduced in overall size; this has been observed as early as the fourth 
month of gestation (Engidawork & Lubec, 2003; Guihard-Costa, Khung, 
Delbecque, Ménez, & Delezoide, 2006). The reduction in overall brain size 
correlates to neuronal hypocellularity, most likely due to failures of neurogenesis 
in utero (Schmidt-Sidor, Wisniewski, Shepard, & Sersen, 1990).  
 Interestingly, not all regions of the brain are equally affected by Down 
syndrome: at birth, the cerebellum is disproportionately small; in adulthood, the 
hippocampus (Dierssen, 2012). Mouse models of Down syndrome recapitulate 
these phenotypes. In one of the Down syndrome mouse models, Ts65Dn, there 
are fewer hippocampal granule neurons during early development and fewer 
proliferating hippocampal cells postnatally (Clark, Schwalbe, Stasko, Yarowsky, 
& Costa, 2006; Insausti et al., 1998; Lorenzi & Reeves, 2006; Rueda, Mostany, 
Pazos, Flórez, & Martínez-Cué, 2005). Contestabile found in both human fetal 
brains and mouse that proliferating hippocampal cells spent a reduced amount 
of time in the synthesis (S) phase of the cell cycle, suggestive of a general timing 
deficit in the cell cycle (Contestabile et al., 2007).  
The conspicuously small cerebellum in Down syndrome also correlates to 
hypocellularity, specifically, a decreased number of cerebellar granule cells and 
Purkinje cells (Baxter, Moran, Richtsmeier, Troncoso, & Reeves, 2000). Offering at 
least part of an explanation, Roper found that cerebellar granule cells have a 
weakened, dose-dependent response to the mitogenic effects of Sonic hedgehog 
(SHH) (Roper et al., 2006). Using a Down syndrome mouse model, Das 
discovered that boosting the SHH signal in newborn mice with a synthetic 
activator, SAG 1.1, corrected adult cerebellar hypocellularity (Das et al., 2013). 
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The restoration of near normal cell counts in the adult cerebellum, unexpectedly, 
did not correspond to any improvements in cerebellar dependent behavioral 
tasks, but rather, led to stark improvements in hippocampal-dependent cognitive 
performance (Das et al., 2013). It is not clear why Down syndrome mice have an 
attenuated response to SHH, nor why improving cerebellar morphology 
improved hippocampal-dependent behavioral tasks, but this is a rich area for 
future investigation. 
 
Altered Neurotransmitter Systems  
Abnormalities in embryonic neurodevelopment underlie much of the 
brain dysmorphology observed in infants with Down syndrome, and strongly 
contribute to cognitive impairment in patients with Down syndrome. Yet the 
brain is a remarkably responsive organ, subject to constant, fine change 
throughout a lifespan. While prenatally “curing” Down syndrome is neither 
ethically, nor practically possible, identifying postnatal treatments for Down 
syndrome—cognitive deficits in particular—is a reasonable goal. Many of the 
current therapeutic options for enhancing cognition in Down syndrome rely on 
correcting altered neurotransmitter systems—GABAergic and serotonergic, in 
particular.  
Down syndrome mice have fewer hippocampal excitatory synapses and 
altered connectivity of hippocampal inhibitory synapses (Dierssen, 2012). These 
morphological differences likely underlie the increased hippocampal inhibition 
and alterations in hippocampal synaptic plasticity observed in rodents. Given 
these results, several labs have sensibly attempted to pharmacologically curtail 
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excessive GABA inhibition with GABAA receptor antagonists or selective 
negative allosteric regulators. In mice, reducing excessive GABA signaling leads 
to impressive recovery of hippocampal physiological and behavioral deficits 
(Braudeau et al., 2011; Fernandez et al., 2007). Regrettably, these improvements 
in cognition following pharmacological inhibition of excessive GABA signaling 
have not extended to humans with Down syndrome; and clinical trials have been 
shelved for the moment (Antonarakis, 2017). 
In addition to alterations in GABAergic signaling, Down syndrome 
humans and mice also show alterations in serotonergic signaling, at least 
partially caused by reduced expression of the serotonergic receptor, 5-HT1A 
(Bar-Peled et al., 1991; Bianchi et al., 2010; Risser, Lubec, Cairns, & Herrera-
Marschitz, 1997). Increasing extracellular serotonin with selective serotonin 
reuptake inhibitors (SSRIs) is linked to hippocampal neurogenesis (Malberg, 
Eisch, Nestler, & Duman, 2000; Santarelli et al., 2003). Several groups working 
with Down syndrome mouse models have found that treatment with SSRIs 
restores hippocampal cell proliferation deficits and 5-HT1A receptor expression 
and improves learning and memory behaviors (Bianchi et al., 2010; Clark et al., 
2006). Given that SSRIs are safe, widely used, and already approved, they are an 
attractive therapeutic option and likely to be explored in clinical trials in the near 
future.   
  
Neurodegeneration 
Nearly all individuals with Down syndrome develop Aβ plaques, 
neurofibrillary tangles, and neurodegeneration—in short, all of the 
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neuropathological hallmarks of Alzheimer’s disease—by their 40s; by age 55-60, 
most exhibit symptoms of dementia (Hartley et al., 2015). Though the molecular 
underpinnings of Alzheimer’s disease are complex, amyloid precursor protein, 
APP, encoded on the 21st chromosome, is strongly associated with the disorder. 
Proteolysis of APP generates several fragments, the most pathologic of which is 
Aβ. The amyloid hypothesis (longstanding, though not without controversy) 
posits that accumulation of Aβ initiates the development of Alzheimer’s disease 
(Querfurth & LaFerla, 2010). Overexpression of APP In Down syndrome is 
thought to lead to increased generation of the toxic Aβ product (Prasher et al., 
1998). The link between Alzheimer’s disease, or “premature senility,” and Down 
syndrome is old and (J. Fraser & Mitchell, 1876). The importance of APP to both 
disorders has also been appreciated for decades (Glenner & Wong, 1984; Masters 
et al., 1985). Nevertheless, there are some differences between Down syndrome-
associated Alzheimer’s disease (DSAD) and the more common late-onset 
Alzheimer’s disease (LOAD) found in the euploid population. For one, Aβ 
deposition in patients with Down syndrome begins much earlier than in the 
general population, with some studies finding Aβ deposits in Down syndrome 
brains as early as the age of 12 (Lemere et al., 1996). Further, less 
neurodegeneration is observed in DSAD than in LOAD, though patients with 
Down syndrome have fewer neurons to begin with (Mann, Yates, Marcyniuk, & 
Ravindra, 1987). 
 Overexpression of other 21st chromosome genes may also contribute to 
Alzheimer’s-associated neurodegeneration observed in older adults with Down 
syndrome. For instance, the kinase, DYRK1A, phosphorylates several splicing 
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factors, which predispose the tau protein to abnormal hyperphosphorylation (F. 
Liu et al., 2008). A microtubule associated protein, tau normally promotes the 
assembly and stability of microtubules—the beams of the cell. 
Hyperphosphorylated tau, however, loses its affinity for microtubules and is 
more prone to forming the aggregates observed in neurofibrillary tangles 
(Querfurth & LaFerla, 2010). Liu discovered that DYRK1a phosphorylated tau at 
several sites in vitro; these sites were also hyperphosphorylated in the brains of 
adults with Down syndrome (F. Liu et al., 2008). 
 Finally, expression levels of synaptojanin, SYNJ1, have been linked to 
Alzheimer’s disease. SYNJ1 is a phosphatase, which acts on a key synaptic 
molecule, PIP2 (phosphatidylinositol 4,5-biphosphate) (Cremona et al., 1999). 
Interestingly, decreased levels of SYNJ1 in haplosufficient mice appear to protect 
against the synaptotoxicity of Aβ (Berman et al., 2008). 
An increased understanding of 21st chromosome genes—or related 
pathways—that mediate neurological development, neuronal function, or 
neurodegeneration, thus, enriches our understanding of Down syndrome and 
can potentially lead to therapeutic options to address aspects of the disorder. 
 
APPROACHES TO IDENTIFYING CANDIDATE GENES AND PATHWAYS 
There are several different approaches to identifying candidate genes or 
pathways of interest to Down syndrome. Results from any one of these strategies 
can lead to fertile lines of inquiry in others.  
 
HSA21 Gene Expression 
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Traditionally, it was assumed that an additional 21st chromosome would 
result in the expression of triplicated genes at 1.5 times the typical amount. As 
transcriptome profiling has demonstrated, this is largely, but not entirely true 
(Lockstone et al., 2007; Mao, Zielke, Zielke, & Pevsner, 2003). More recently, the 
Herwig group found that trisomy of the 21st chromosome was associated with 
dysregulation of genes on other chromosomes (Vilardell et al., 2011). 
Overexpression of transcription factors or other proteins exerting broad 
regulatory roles could possibly explain some of this genome wide dysregulation. 
Several transcription factors are known to be encoded on HSA21, including 
three—RUNX1, BACH1, and ERG—associated with an increased risk for 
leukemia in Down syndrome (Dierssen, 2012).  
 
Functional Classification 
Functional classification of genes on the 21st chromosome can also be used 
to predict candidate genes contributing to neurological phenotypes in Down 
syndrome. For instance, several ion channel subunits are encoded on the 21st 
chromosome, including a subunit of the G-protein coupled inwardly rectifying 
potassium channel, GIRK2. Cooper found that mice trisomic for Kcnj6, the gene 
encoding GIRK2, displayed deficits in hippocampal-dependent learning and 
memory tasks and had altered synaptic plasticity—phenotypes also observed in 
Down syndrome mouse models (Cooper et al., 2012). Genes encoding cell 
adhesion molecules have also been proposed as candidates contributing to 
neurological phenotypes in Down syndrome; indeed, overexpression of the 
Down syndrome cell adhesion molecule, DSCAM, has been shown to inhibit 
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dendritic branching in mouse hippocampal neurons (Alves-Sampaio, Troca-
Marín, & Montesinos, 2010). Reduced dendritic branching is another 
characteristic of adults with Down syndrome (Becker, Mito, Takashima, & 
Onodera, 1991). Finally, genes encoding proteins with master regulatory 
functions can contribute to neurodevelopmental and cognitive deficits in Down 
syndrome. The kinase, DYRK1A, is one of the best characterized genes in this 
category; I will discuss its functional role in the following section.  
 
Genetic Dissection 
Genetic dissection is a tried and true approach for discovering candidate 
genes contributing to a phenotype of interest. In the baldest of terms, this 
technique involves breaking a gene and observing the effects. Given their relative 
simplicity, invertebrates have been particularly well-suited to this approach; 
several genes critical for neurodevelopment and cognitive function in Down 
syndrome were initially characterized in invertebrates.  
Genetic screening in Drosophila identified the gene mnb (minibrain), 
required for postembryonic neurogenesis (Tejedor et al., 1995). Subsequent 
research in mice, identified the ortholog of mnb, Dyrk1a, and found that it, too, 
played a pivotal role in neurogenesis (Shindoh et al., 1996; W. J. Song, Chung, & 
Kurnit, 1997). DYRK1A—dual-specificity tyrosine phosphorylation-regulated 
kinase 1A—is involved in neurodevelopment, motor function, and cognition and 
has been rigorously studied within the context of Down syndrome (Ahn et al., 
2006; Altafaj et al., 2001).  
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Genetic screening in C. elegans has also been fruitful. In his seminal work, 
Sydney Brenner identified and characterized unc-26, later shown to encode 
synaptojanin (Brenner, 1974). A phosphatase, synaptojanin plays a key role in 
synaptic vesicle recycling and modulates levels of second messenger molecules 
within the synapse. In mice, overexpression of SYNJ1 causes memory deficits 
reminiscent of those in Down syndrome mouse models (Voronov et al., 2008). 
 
C. ELEGANS AS A MODEL ANIMAL FOR NEUROGENETICS 
Superficially, C.elegans is an unassuming animal. In the wild, this small, 
transparent roundworm lives out its brief life amid decomposing organic matter. 
Yet its simplicity belies its utility for understanding the genetic basis of nervous 
systems. Adult hermaphroditic worms have 302 neurons, stereotypically located. 
Systematic ablation of these neurons has revealed the function of many of them. 
Displaying truly heroic effort, White determined the wiring diagram of C.elegans 
by reconstructing serial electron micrographs (J. G. White, Southgate, Thomson, 
& Brenner, 1986). Thus, we know the identity of every neuron, its location within 
the animal, and with whom it communicates.  
Because of the compactness of the worm’s nervous system, deficits in a 
specific behavior can often indicate deficits in a specific neuron or circuit. The 
specificity of behavioral outputs in worm is impressive; and combined with the 
power of modern genomics and genetics, remarkable. Examination of simple 
behaviors of mutant worms has helped to identify several genes with critical 
roles in the nervous system, including the first GABA transporter (unc-47) and 
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the first glutamate transporter, (eat-4) (Rankin, 2002). Importantly, both of these 
genes were later found to be conserved in mammals.  
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Figure 1.1. Mouse models of Down syndrome and the Down syndrome 
“critical region.” Depicted here is the human 21st chromosome (Human 21) with 
the purported Down syndrome critical region (DSCR) shown in white. The 
corresponding region triplicated in Ts65Dn, a popular mouse model of Down 
syndrome, is adjacent. In Ms1Rhr/Ts65Dn, the DSCR has been crossed out. In 
Ts1Rhr, only the DSCR is triplicated. From (Olson et al., 2004). 
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ABSTRACT 
Individuals with Down syndrome have neurological and muscle impairments 
due to an additional copy of the human 21st chromosome (HSA21). Only a few of 
the ~200 HSA21 genes encoding protein have been linked to specific Down 
syndrome phenotypes, while the remainder are understudied. To identify poorly 
characterized HSA21 genes required for nervous system function, we studied 
behavioral phenotypes caused by loss-of-function mutations in conserved HSA21 
orthologs in the nematode Caenorhabditis elegans. We identified ten HSA21 
orthologs that are required for neuromuscular behaviors: cle-1 (COL18A1), cysl-2 
(CBS), dnsn-1 (DONSON), eva-1 (EVA1C), mtq-2 (N6ATM1), ncam-1 (NCAM2), 
pad-2 (POFUT2), pdxk-1 (PDXK), rnt-1 (RUNX1), and unc-26 (SYNJ1).  We also 
found that three of these genes are required for normal release of the 
neurotransmitter acetylcholine. This includes a known synaptic gene unc-26 
(SYNJ1), as well as uncharacterized genes pdxk-1 (PDXK) and mtq-2 (N6AMT1). 
As the first systematic functional analysis of HSA21 orthologs, this study may 
serve as a platform to understand genes that underlie phenotypes associated 
with Down syndrome.  
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INTRODUCTION 
Down syndrome (DS) is the most common genetic cause of intellectual 
disability, occurring with an incidence as high as 1 in ~700 live births in the 
United States (Canfield et al., 2006). Although DS is defined by a variety of 
symptoms, all individuals with DS display varying degrees of intellectual 
disability, including learning and memory problems, and upon middle age they 
develop Alzheimer’s-like dementia (Coyle, Oster-Granite, Reeves, & Gearhart, 
1988). In addition, all individuals with DS experience neuromuscular symptoms. 
For instance, DS is the leading cause of neonatal heart defects, leading to a high 
infant mortality rate without surgical intervention (Korenberg et al., 1994; Vis et 
al., 2009). Another common symptom of DS, hypotonia (muscle weakness), 
causes deficits in both gross and fine motor skills, leading people with DS to 
have trouble speaking, writing, and moving efficiently (Pitetti, Climstein, Mays, 
& Barrett, 1992).  
For over fifty years, researchers have known that an extra copy of the 21st 
chromosome (Human somatic autosome 21, HSA21) underlies DS (Jacobs, Baikie, 
Court Brown, & Strong, 1959).  However, the precise mechanisms by which 
trisomy 21 causes DS-associated phenotypes are largely unknown. An early 
hypothesis explaining the link between DS and trisomy 21 argued that the 
burden of the extra genetic material strains cellular processes in the DS patient, 
resulting in all DS symptoms (Patterson, 2009; Shapiro, 1975). Yet research on 
rare individuals with partial trisomy 21 has shown that the amount of extraneous 
genetic material does not readily account for the collection of symptoms 
associated with DS nor their degree of manifestation (Korenberg et al., 1994; Lyle 
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et al., 2009). A second hypothesis posited that a region containing about 30 
protein-coding genes on HSA21, termed the Down Syndrome Critical Region 
(DSCR), is responsible for all DS-associated phenotypes. This was based on the 
genomic area of overlap shared between two individuals with partial trisomy 21 
who still displayed many DS phenotypes (Rahmani et al., 1989). A mouse model 
(Ts1Rhr) containing trisomy of only DSCR orthologous genes was developed to 
investigate the role of the DSCR (Olson et al., 2004). Many, but not all of the 
phenotypes expected for DS were observed in this mouse model, suggesting that 
the DSCR is important, but not solely responsible for the whole set of DS-
associated phenotypes (N. P. Belichenko et al., 2009; Olson et al., 2004). Mouse 
models of DS trisomic for syntenic regions of HSA21 other than the DSCR have 
also been instrumental in the analysis of the genetic origins of DS-related 
phenotypes, including craniofacial defects (Richtsmeier, Baxter, & Reeves, 2000; 
Richtsmeier, Zumwalt, Carlson, Epstein, & Reeves, 2002), cerebellar cell loss 
(Baxter et al., 2000), as well as synaptic and hippocampal circuit dysfunction (P. 
V. Belichenko et al., 2004; Demas, Nelson, Krueger, & Yarowsky, 1998; 
Escorihuela et al., 1995; Holtzman et al., 1996; Reeves et al., 1995).  
Studies focusing on individual orthologous genes on HSA21 in animal 
models have also provided insight into the genetic basis of DS phenotypes. 
Single gene studies are attractive because the underlying genetic contributions of 
a phenotype are more readily dissected; single genes can also offer clearer insight 
into pharmacotherapeutic targeting of specific gene products (Dierssen, 2012). 
Determining the biological function of a single gene can be approached with 
either a loss-of-function or gain-of-function (e.g. overexpression) approach. Both 
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have merit. For genes for which there is no or incomplete redundancy, loss-of-
function experiments provide valuable insight into gene function. Several HSA21 
orthologous genes were initially characterized in this way in invertebrate 
models. Early work conducted in Drosophila melanogaster, for instance, revealed 
that the gene mnb (minibrain) played a critical role in postembryonic 
neurogenesis (Tejedor et al., 1995). Subsequent research linked fly mnb to its 
mammalian orthologue, DYRK1A; and, as in fly, loss of Dyrk1a in mice was also 
shown to result in abnormal neurogenesis (Shindoh et al., 1996; W. J. Song et al., 
1997; 1996). Intriguingly, overexpression of Dyrk1a alone in a mouse transgenic 
model results in neurodevelopmental delay, motor abnormalities, and spatial 
memory defects, which suggest a potential role in DS-associated cognitive 
impairment (Ahn et al., 2006; Altafaj et al., 2001). Similarly, the neuronal role of 
the basic helix-loop-helix protein, SIM2 (single-minded family bHLH 
transcription factor 2) on HSA21 was also initially identified in fly. Mutations in 
the fly ortholog, sim, impair development of cells in the midline of the central 
nervous system (Crews, Thomas, & Goodman, 1988; Thomas, Crews, & 
Goodman, 1988). Subsequent experiments identified the mouse homolog and 
found that a targeted deletion of the gene led to craniofacial malformations (H. 
Chen et al., 1995; Shamblott, Bugg, Lawler, & Gearhart, 2002). Overexpression of 
Sim2 in mouse also recapitulated behavioral aspects of established mouse models 
of DS including reduced exploratory behaviors and hypersensitivity to pain 
(Chrast et al., 2000). Single gene studies and invertebrate models, thus, 
complement research with traditional DS mouse models that overexpress 
combinations of many HSA21 genes.  
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Despite this progress, the in vivo function of a majority of genes on HSA21 
remains unknown. It is impractical to perform a systematic analysis of gene 
function through gene knock down in mouse models. Therefore, we set out to 
gain knowledge about roles of HSA21 genes by studying the function of HSA21 
orthologs in the nematode Caenorhabditis elegans, a more tractable genetic model.   
C. elegans is a well-established genetic model and exhibits sequence 
similarity with at least 42% of genes associated with human disease (Culetto & 
Sattelle, 2000). Additionally, the C. elegans nervous system is compact, with only 
302 neurons (White et al., 1985). Because any one neuron may be connected to 
any other by only 6 or fewer synapses, defects in even a single neuron are often 
detectable with behavioral phenotypes such as locomotion (B. L. Chen, Hall, & 
Chklovskii, 2006). Proper function of the muscular feeding organ, called a 
pharynx, also requires precise communication between neurons and muscle. 
Defects in pharyngeal pumping have helped identify a conserved vesicular 
glutamate transporter (e.g. eat-4) and nicotinic cholinergic receptor subunits 
(Avery & You, 2012). Finally, C. elegans synapses are also similar to those of 
mammals. Genetic screens using the acetylcholinesterase inhibitor aldicarb in 
worm have identified genes critical for synaptic function in mammals 
(Richmond, 2005). 
Because the in vivo functions of HSA21 genes have not been systematically 
studied, we suspected that some HSA21 genes with important neuronal or 
muscle roles were overlooked. The goal for our study was to determine HSA21 
orthologs involved in neuronal and/or muscle function. To this end, we analyzed 
behavioral phenotypes induced by loss-of-function mutations and found that 
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disruption of several uncharacterized HSA21 orthologs in worm yielded 
significant neuromuscular phenotypes. To determine if any HSA21 orthologs 
were involved in neurotransmission, we performed a second screen on loss-of-
function mutants measuring their sensitivity to the acetylcholinesterase inhibitor 
aldicarb. We identified three genes involved in neurotransmitter release: unc-26 
(SYNJ1), which has previously been characterized, and mtq-2 (N6AMT1) and 
pdxk-1 (PDXK), both of which have received minimal attention. The results from 
our behavioral and pharmacological screens may inform predictions for which 
genes contribute to the neuronal and muscle phenotypes associated with DS.  
 
RESULTS 
Estimate of HSA21 Protein-Coding Genes 
To determine a conservative number of protein-coding genes on the 
human 21st chromosome, we queried both Ensembl and Human Gene 
Nomenclature Committee (HGNC) databases and selected only those proteins 
reviewed by SwissProt. This public database provides manual curation and 
review for each protein, which ensures high quality, non-redundant entries 
(UniProt Consortium, 2015). This strategy yielded a total number of 213 protein-
coding genes on the 21st chromosome APPENDIX A, APPENDIX D, APPENDIX 
E. 
 
Determining HSA21 orthologs in C. elegans  
To identify putative worm orthologs of protein-coding genes on the 
human 21st chromosome (HSA21), we relied on OrthoList, a publicly available 
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database. OrthoList compiles results from a meta-analysis of four orthology 
prediction programs—Ensembl Compara, OrthoMCL, InParanoid, and 
Homologene (Shaye & Greenwald, 2011). OrthoList predicts at least one worm 
ortholog for 85 of the 213 HSA21 protein-coding genes (blue and light-grey wedges 
in Figure 2.1). HSA21 encodes 48 predicted keratin proteins, which have no 
orthologs in worm (Shaye & Greenwald, 2011). Excluding these keratin-encoding 
genes, C. elegans has at least one predicted orthologous gene to 52% of the 
remaining HSA21 genes (Figure 2.1). To focus our screen on genes that most 
likely share conserved functions, we chose to study orthologous genes existing in 
any relationship except many-to-many as defined by the InParanoid algorithm 
(Sonnhammer & Östlund, 2015). This included one-to-one, one-to-many, and 
many-to-one relationships. By this measure, InParanoid identifies 47 unique 
HSA21 genes with predicted orthologs in worm (three wedges highlighted by red 
arc in Figure 2.1). These 47 HSA21 human genes are represented by 51 genes in 
worm.  
The imperfect evolutionary matchup of HSA21 human genes with 
C. elegans genes results in many human genes being orthologous to multiple 
worm genes (Figure 2.1 and see Orthologs sheet in APPENDIX A. For instance, 
the human gene CBS is predicted to be orthologous to four paralogs: cysl-1, cysl-
2, cysl-3, and cysl-4. There was only one case of paralogous human genes in our 
analysis: both RRP1 and RRP1B human genes are predicted to be orthologous to 
the single worm gene C47E12.7. Of the 47 HSA21 human genes, 19 are 
orthologous one-to-one with worm genes, 25 are orthologous many-to-one with 
25 worm genes, and 3 are orthologous one-to-many with 8 worm genes.  
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An additional 38 HSA21 human genes had one or more orthologs 
predicted by the Ortholist algorithm in C. elegans (depicted by light-grey wedge in 
Figure 2.1 and listed in APPENDIX D.  Because most of these HSA21 human 
genes are predicted to be orthologous to multiple worm genes, orthology of the 
38 human genes expands to represent 111 worm genes in total. For example, the 
human gene ABCG1 is predicted to be orthologous to four paralogs: wht-2, wht-3, 
wht-6, and wht-8. In four cases, distinct but paralogous human genes are 
orthologous to the same worm gene. For instance, both OLIG1 and OLIG2 human 
genes are both predicted to be orthologous to hlh-16 in worm. To focus our 
screen, we did not pursue these genes in this study.  
Lastly, we found that an additional 128 protein-coding genes on HSA21 
have no predicted Ortholist otholog in C. elegans (depicted by black wedge in 
Figure 2.1 and listed in APPENDIX E.   
Taken together, our analysis above shows that discounting the keratin 
genes, about half of the 213 HSA21 human genes are predicted to be orthologous 
to genes in C. elegans. We focused on the set of 47 HSA21 human genes 
represented by 51 InParanoid orthologs in worm in this study. 
 
HSA21 orthologs required for viability in C. elegans 
 Before embarking on our behavioral screen using mutants, we first sought 
to determine which of the 51 HSA21 predicted orthologs are required for 
viability using RNAi (APPENDIX B). Previous large-scale and small-scale RNAi 
screens studied 38 of the 51 genes (Ceron et al., 2007; Cui et al., 2008; A. G. Fraser 
et al., 2000; Gottschalk et al., 2005; Kamath et al., 2003; Maeda, Kohara, 
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Yamamoto, & Sugimoto, 2001; Simmer et al., 2003; Sönnichsen et al., 2005). These 
studies reported that RNAi treatments caused viability phenotypes for 15 of 
these orthologs that severely effect development, growth, and/or reproduction. 
These include embryonic and larval lethal, larval arrest, severe growth defects, 
and sterility phenotypes. For an additional 24 orthologs, these studies reported 
that RNAi treatment caused an apparent wild-type phenotype. Out of the 51 
HSA21 worm orthologs, 14 were not studied in previous RNAi screens, in part, 
because no RNAi reagent was available at the time.  
To confirm and extend these results we performed RNAi on all 51 HSA21 
orthologs for which an RNAi clone was currently available using 45 unique 
RNAi treatments (APPENDIX B). We found concordance for 82% or 37 out of the 
45 genes tested. Only 4% or two of our RNAi treatments produced results 
discrepant from previous studies. RNAi treatment of irk-1 (KCNJ6) or chaf-2 
(CHAF1B) were previously reported to cause severe viability phenotypes 
whereas we found no effect for both treatments (Gottschalk et al., 2005; Kamath 
et al., 2003; Nakano, Stillman, & Horvitz, 2011; Sönnichsen et al., 2005). We found 
that 14 out of 16 of the genes that caused inviability in our study or in previous 
studies when knocked down, including irk-1 and chaf-2, lacked a publically 
available viable loss-of-function mutant. This finding is consistent with the idea 
that these genes are probably essential. Two additional genes, dip-2 and dnsn-1, 
had corresponding viable predicted null mutants, but we and others found that 
they caused inviability when knocked down by RNAi (Simmer et al., 2003; 
Kamath et al., 2003); perhaps this reflects a viability phenotype with low 
penetrance. We acknowledge that additional genes may later prove to represent 
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essential genes, especially if the gene lacks a corresponding null mutant, e.g. 
pdxk-1. Overall our RNAi screen confirms most viability phenotype results from 
previous studies and suggests that at least 33% or 15 out of 45 of tested HSA21 
predicted orthologs are inviable when reduced in function in C. elegans. 
 
HSA21 orthologs required for neuromuscular behaviors 
Having identified which HSA21 orthologs are probably essential, we 
turned next to investigate the in vivo function of nonessential HSA21 orthologs. 
We tested every publically available, viable mutant, which represented 27 genes 
in total (APPENDIX C). We performed a phenotypic screen, selecting a battery of 
three behavioral assays to probe neuromuscular function. Overall, we identified 
ten mutants that were significantly defective in performance in these assays. To 
better link genotype to phenotype, we generated transgenic rescue lines for any 
mutant deficient in any of the three behaviors and/or tested additional mutant 
alleles if available. 
We first examined short-term locomotion with a radial dispersion assay, 
which provides a general metric of locomotor function over 10 minutes. In this 
assay, the distance displaced over time reflects a combination of locomotor traits 
including frequency of body bends, reversal rate, and coordination (Topalidou et 
al., 2017). Aside from the well-characterized uncoordinated mutant unc-26, an 
ortholog of synaptojanin (Harris, Hartwieg, Horvitz, & Jorgensen, 2000), we also 
identified two other mutants with rescuable deficits in radial dispersion: cysl-2 
(CBS) and rnt-1 (RUNX1) (Figure 2.2).  
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Second, we examined the longer-term behavior of mutants with an 
exploration assay. This assay measures not only the general locomotor ability of 
worms, but also their tendency to explore a cultivation plate seeded with 
bacterial food over the course of 16 hours. While foraging, worms alternate 
between two states: roaming—an active state characterized by a burst of 
locomotion associated with a search for food—and dwelling—a more passive 
state associated with feeding or resting after satiation. Time spent in roaming 
and dwelling states depends on integrating internal neuromodulatory cues with 
external sensory cues. The absence of such sensory transduction leads to 
extended dwelling as observed in the tax-4 mutant, which encodes a cyclic 
nucleotide-gated channel subunit (Fujiwara, Sengupta, & McIntire, 2002; Greene 
et al., 2016). In contrast, mutants with constitutive sensory input, such as the egl-4 
mutant, show extended roaming (Fujiwara et al., 2002). Extended dwelling or 
roaming compared to wild-type behavior can be quantified by counting the 
number of squares that a worm traverses over 16 hours (Figure 2.3).  
As expected, we found that the uncoordinated mutant unc-26 (SYNJ) 
moved poorly in the exploration assay. We also identified the following four 
mutants with rescuable defects in extended dwelling: eva-1 (EVA1C), dnsn-1 
(DONSON), mtq-2 (N6AMT1), and pdxk-1 (PDXK1) (Figure 2.3). These mutants 
appeared to move superficially similar to wild type, suggesting sensory-motor 
integration deficits. We rescued the exploration behavior of each mutant by 
transformation with wild-type copies of corresponding transgenes (Figure 2.3). 
To obtain a measure of neuromuscular activity that was distinct from 
locomotion, we performed a feeding assay. C. elegans pumps bacterial food into 
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its gut through a feeding organ called a pharynx that uses muscles and neurons 
distinct from those needed for locomotion. The rhythmic contractions and 
relaxations of the pharynx require precise coordination between pharyngeal 
neurons and muscle. We identified the following four genes required for normal 
pharyngeal pumping: cle-1 (COL18A1), mtq-2 (N6AMT1), ncam-1 (NCAM2), and 
pad-2 (POFUT2) (Figure 2.4). Independent null alleles of mtq-2 displayed similar 
deficits in pharyngeal pumping (Figure 2.4). Transformation with wild-type 
copies of each gene rescued the slow pumping phenotype of each mutant (Figure 
2.4). 
In summary, by screening three behaviors, we identified ten genes total 
with rescuable defects in one or more behaviors designed to probe 
neuromuscular function. Several among these genes—dnsn-1 (DONSON), pdxk-1 
(PDXK), and mtq-2 (N6AMT1)—are poorly characterized, yet may mediate 
nervous system function, development, or both.  
 
HSA21 orthologs required for proper synaptic function 
To determine the potential role of HSA21 predicted orthologs in 
neurotransmission, we tested whether the same set of loss-of-function mutants 
displayed altered sensitivity to paralysis by the acetylcholinesterase inhibitor 
aldicarb. Many genes critical for key steps in synaptic function have been 
identified by testing mutants for altered sensitivity to aldicarb (Richmond, 2005). 
Aldicarb causes paralysis of worms by chronically activating body-wall muscle 
after the prolonged presence of acetylcholine at the neuromuscular junction. 
Mutants defective in any aspect of synaptic transmission show altered sensitivity 
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to paralysis by aldicarb. For instance, mutants defective in acetylcholine release 
show resistance to paralysis by aldicarb due to decreased levels of acetylcholine 
in the cleft (Mahoney, Luo, & Nonet, 2006). Conversely, mutations that increase 
acetylcholine release lead to increased sensitivity to paralysis (Gracheva et al., 
2006; McEwen, Madison, Dybbs, & Kaplan, 2006).  
We identified three mutants that displayed significant resistance to 
paralysis by aldicarb: unc-26 (SYNJ1), mtq-2 (N6AMT1), and pdxk-1 (PDXK). 
Compared to wild type, these three mutant strains took longer to paralyze when 
treated with aldicarb (Figure 2.5). By contrast, 24 other mutants became 
paralyzed at a similar rate as wild-type worms. Although we measured the 180-
minute time course of paralysis for all 27 mutants, we plot only the percent 
moving on aldicarb at the 180-minute time point for ease of comparison (Figure 
2.5). Transformation of mtq-2 and pdxk-1 mutants with wild-type copies of these 
genes rescued aldicarb sensitivity for each mutant (Figure 2.6). As a 
complementary strategy to the mutant screen, we also tested aldicarb sensitivity 
for HSA21 predicted orthologs using RNA interference. With this independent 
approach, we confirmed the aldicarb resistance of pdxk-1 (PDXK-1) and observed 
suggestive results for mtq-2 (MTQ-2) (Figure 2.7). 
We found that RNAi treatment targeting ncam-1 provided resistance to 
aldicarb; however, we also found that a null allele of ncam-1 failed to show any 
resistance to paralysis by aldicarb (Figure 2.5 and Figure 2.7) suggesting that our 
RNAi result for ncam-1 was a false positive. This result is consistent with a 
previous RNAi study that found negative results for ncam-1 on aldicarb (Sieburth 
et al., 2005). 
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Resistance to aldicarb is primarily caused by presynaptic deficiencies in 
acetylcholine release or postsynaptic deficiencies in receptor response (Mahoney 
et al., 2006). To distinguish between these possibilities, we measured the 
sensitivity of mutants to paralysis by levamisole, a potent agonist for the 
nicotinic cholinergic receptor (Lewis, Wu, Berg, & Levine, 1980). Levamisole 
causes paralysis of wild-type worms by chronically activating body-wall muscle 
irrespective of synaptic release defects. Mutants resistant to paralysis by 
levamisole are most commonly defective in cholinergic receptor signaling or 
muscle function.  
We found that mtq-2, unc-26, and pdxk-1 mutants all displayed wild-type-
like or hypersensitive responses to levamisole (Figure 2.6). These results suggest 
that resistance to aldicarb among these three mutants is due to defective 
presynaptic release of neurotransmitter. 
 
Expression pattern of HSA21 orthologs 
We identified ten genes linked to rescuable neuromuscular defects in our 
study (Table 2.1). Five genes were previously shown to be expressed in the 
nervous system: cle-1 (COL18A1), eva-1 (EVA1C), ncam-1 (NCAM2), pad-2 
(POFUT2), rnt-1 (RUNX1) and unc-26 (SYNJ) (Ackley et al., 2001; Fujisawa, 
Wrana, & Culotti, 2007; Hunt-Newbury et al., 2007; McKay et al., 2003; Menzel et 
al., 2004; Schwarz, Pan, Voltmer-Irsch, & Hutter, 2009). An additional four genes 
had no reported expression patterns: cysl-2 (CBS), dnsn-1 (DONSON), mtq-2 
(N6AMT1), and pdxk-1 (PDXK). To identify the tissues in which these genes may 
function, we generated mCherry transcriptional reporter strains. We found that 
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mtq-2 expressed exclusively throughout the nervous system. Expression 
overlapped with a subset of cholinergic neurons in the head and throughout the 
ventral nerve cord as defined by the Punc-17::GFP reporter (Figure 2.8). 
Expression of mtq-2 mCherry reporter was not observed in GABAergic neurons 
defined by the Punc-47:GFP reporter (Figure 2.8). Interestingly, our mCherry 
reporter for pdxk-1 expressed in GABAergic, but not cholinergic neurons (Figure 
2.8). Our transcriptional reporter for dnsn-1 expressed robustly within the 
developing embryo, but not within the adult nervous system (Figure 2.8). This 
suggests a potential developmental role for this gene. Lastly, we found that our 
mCherry cysl-2 reporter expressed broadly throughout head and body-wall 
muscle (Figure 2.8).  
 
DISCUSSION 
Our research predicts new functional annotation of genes on the human 
21st chromosome by characterizing in vivo roles of putative orthologs in C. 
elegans. Within the field of Down syndrome, research has primarily focused on 
the functions of contiguous groups of genes using mice, such as those included 
in the so-called Down syndrome critical region (DSCR) (X. Jiang et al., 2015). 
Meanwhile, the vast majority of HSA21 genes remain functionally 
uncharacterized. One proven approach to reveal the function of large numbers of 
genes, even at the level of the whole genome, is to study their roles in more 
tractable invertebrate models such as C. elegans. Although several large-scale 
reverse genetics screens in C. elegans have begun to uncover novel in vivo roles 
for thousands of genes, they have focused less explicitly on neuronal phenotypes 
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and excluded more genes than may be generally acknowledged (A. G. Fraser et 
al., 2000; Kamath et al., 2003; Sieburth et al., 2005; Vashlishan et al., 2008). For 
instance, two seminal whole-genome RNAi screens tested only 33 of the 51 
HSA21 orthologs focused on in the current study (A. G. Fraser et al., 2000; 
Kamath et al., 2003). These studies primarily focused on viability phenotypes 
such as gross development and fertility. We expanded this analysis to test an 
additional eight orthologs not tested in these seminal or subsequent RNAi 
studies (Ceron et al., 2007; Gottschalk et al., 2005; Nakano et al., 2011; Pujol et al., 
2001; Rual et al., 2004; Sönnichsen et al., 2005). With the addition of our current 
study, out of the 51 HSA21 orthologs, only five genes remain unstudied using 
RNAi or mutant in any study due to lack of reagents: D1086.9 (CLIC6), H39E23.3 
(CLIC6), Y54E10A.11 (LTN1), Y74C10AL.2 (TMEM50B), and ubc-14 (UBE2G2). 
Overall, however, our results were consistent with earlier studies. We found only 
two discrepancies: previous studies found that RNAi targeting irk-2 and chaf-2 
caused sterility while we found no effect (Gottschalk et al., 2005; Kamath et al., 
2003).  
Other seminal RNAi screens in C. elegans searched for genes critical for 
synaptic transmission. Even though these screens were prodigious, testing 2,068 
genes in total, only five of the HSA21 orthologs: mbk-1, itsn-1, ncam-1, K02C4.3, 
and wdr-4 (Sieburth et al., 2005; Vashlishan et al., 2008) were examined. These 
studies reported negative results for all five genes in agreement with our RNAi 
and mutant findings here. Notably, the synaptic RNAi screens did not test the 
three genes that we found to be critical for normal synaptic transmission: mtq-2, 
pdxk-1, and unc-26. Thus, despite the whole-genome and large-scale nature of 
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previous screens, many genes with important in vivo functions likely remain to 
be discovered using C. elegans. Because our study largely replicated results from 
previous studies, we are optimistic that a systematic approach with C. elegans, as 
used here, may reveal the function of important sets of genes involved in human 
polygenic or chromosomal disorders.  
We also performed several behavioral screens to identify HSA21 predicted 
orthologs that function in nervous system and muscle in ways that previous 
reverse-genetic screens may have missed. This included a radial dispersion assay 
that reflects short-term locomotor ability, an exploration assay that reflects 
longer-term sensory and motor integration, and a feeding assay that probes an 
independent neuromuscular circuit. We identified 10 mutants with deficiencies 
in these behaviors that we were able to rescue and/or confirm with independent 
alleles (Table 2.1): cle-1 (COL18A1), cysl-2 (CBS), dnsn-1 (DONSON), eva-1 
(EVA1C), mtq-2 (N6AMT1), ncam-1 (NCAM2), pad-2 (POFUT2), pdxk-1 (PDXK), 
rnt-1 (RUNX1), and unc-26 (SYNJ). These 10 orthologs are alluring candidate 
genes that may mediate nervous system development and/or function and 
should, thus, be prioritized for further study in worm and mammalian model 
systems. 
In general, our targeted screen of HSA21 orthologs revealed three primary 
findings for the 10 HSA21 orthologs. First, we found genes with established links 
to nervous system function (e.g. cle-1, eva-1, ncam-1, and unc-26). For instance, cle-
1 (COL18A1), eva-1 (EVA1C), and ncam-1 (NCAM2) and have all been linked to 
deficits in axon guidance in worm. The type XVIII collagen gene, cle-1, mediates 
both neuronal and axonal migrations (Ackley et al., 2001). eva-1 encodes a Slit 
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receptor required for axon guidance, and ncam-1 encodes a neural cell adhesion 
molecule that functions redundantly with other cell adhesion molecules to direct 
axonal outgrowth (Fujisawa et al., 2007; Schwarz et al., 2009). Additionally, the 
unc-26 (SYNJ) mutant showed resistance to aldicarb but sensitivity to levamisole 
indicative of presynaptic defects. This is consistent with its known role in 
synaptic vesicle recycling (Harris et al., 2000). 
Second, we uncovered novel neuronal functions for the otherwise well-
characterized HSA21 ortholog rnt-1 (RUNX1). In mammals, the runt-related 
transcription factor RUNX1 plays a vital role in development, including 
regulation of the developing nervous system (Wang & Stifani, 2017). In worm, 
the runt-related transcription factor rnt-1 has also been studied for its role in 
general development, including cell proliferation and male tail development 
(Hajduskova, Jindra, Herman, & Asahina, 2009; Nimmo, Antebi, & Woollard, 
2005). Interestingly, loss of rnt-1 may also cause defects to phasmid neuron 
morphology; however, this was not linked to a detectable behavioral phenotype 
(Hajduskova et al., 2009). The locomotor deficiency that the rnt-1 mutant 
displayed in our radial dispersion assay might be due to developmental defects 
affecting the nervous system.  
Third, whereas the majority of Down syndrome research has focused on 
well-studied genes, we also uncovered novel neuronal functions of three poorly 
characterized HSA21 orthologs that have weak or nonexistent links to the 
nervous system: dnsn-1 (DONSON), mtq-2 (N6AMT1), and pdxk-1 (PDXK). These 
three genes are so uncharacterized that they only had placeholder names when 
we started our study. To encourage their study, we renamed them based on their 
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predicted orthologs: C24H12.5 to dnsn-1, C33C12.9 to mtq-2, and F57C9.1 to pdxk-
1. Below, we highlight their functions in the limited context of their orthologs in 
other species. 
DONSON was only recently found to encode a novel fork protection 
factor that underlies microcephalic dwarfism, yet it remains deeply understudied 
(Reynolds et al., 2017). The worm ortholog, dnsn-1, is equally uncharacterized. 
We found dnsn-1 mutants to exhibit extended dwelling in an exploration assay 
and observed expression of dnsn-1 in the developing embryo, but not the adult 
animal. Thus, our data are suggestive of a role within the nervous system and 
possibly within the developing nervous system.  
PDXK phosphorylates vitamin B6, converting it to PLP (pyridoxal-5’-
phosphate), a key cofactor in the metabolism of hundreds of enzymatic reactions, 
including synthesis of neurotransmitters (Cao, Gong, Tang, Leung, & Jiang, 2006; 
Shetty & Gaitonde, 1980). Loss of PDXK in mice causes pre-weaning lethality, so 
its behavioral role has not yet been studied in mammals (Mouse Genome 
Informatics and the International Mouse Phenotyping Consortium (IMPC)). 
Interestingly, PDXK is predicted to be haploinsufficient in mammals and is a 
candidate dose-sensitive gene contributing to phenotypes in Down syndrome 
(Antonarakis, 2016). We found that pdxk-1 mutant worms showed general 
deficiencies in behaviors as well as specific defects in synaptic transmission as 
determined by aldicarb screening. Our finding that the pdxk-1 mutant was 
readily paralyzed by levamisole suggests a presynaptic role for pdxk-1 in the 
nervous system. 
 40 
To our knowledge, MTQ-2 has not been implicated in nervous system 
function in any animal model. The mammalian ortholog of mtq-2, N6AMT1, was 
originally named on the basis of the presence of an amino acid motif 
(D/N/S)PP(Y/FW) which is characteristic of adenine methyltransferases (Bujnicki 
& Radlinska, 1999; Kusevic, Kudithipudi, & Jeltsch, 2016). However, no evidence 
of adenine methylation by MTQ-2 protein has been found in either yeast or 
mouse, suggesting that N6AMT1 may be a misnomer (P. Liu et al., 2010; Ratel et 
al., 2006). Instead, MTQ-2 has been shown to post-translationally modify ERF1 
(eukaryotic release factor 1) by methylating a universally conserved glutamine 
residue on ERF1 (Heurgué-Hamard et al., 2006); (Polevoda, Span, & Sherman, 
2006). More recently, the mouse ortholog of MTQ-2 was shown to methylate 
many additional substrates in vitro and CHD5 (chromodomain helicase DNA-
binding protein 5) and NUT (nuclear protein in testis) in vivo. This raises the 
possibility that MTQ-2 may modulate more proteins than previously thought 
(Kusevic et al., 2016). Here we have identified behavioral phenotypes of mtq-2 
mutants that support a neuronal role in C. elegans. Additionally, we found that a 
reporter for mtq-2 widely expresses throughout the nervous system, specifically 
in a subset of cholinergic neurons. The high conservation (47% amino acid 
identity between human isoform 1 and worm) of MTQ-2 as well as many of its 
predicted interacting partners warrant more detailed study to determine how it 
functions in synaptic transmission. C. elegans may provide an especially 
informative system to study mtq-2 as deletion of N6AMT1 causes embryonic 
lethality in KO mice (P. Liu et al., 2010).  
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There is a rich body of literature in the field of Down syndrome devoted 
to exploring the underlying genetic contributions of the disorder. Single gene 
studies have helped to elucidate the role of individual genes such as DYRK1A, 
both as a transgenic single gene triplication and within a trisomic context, and 
have led to the development of pharmacotherapeutic treatments (Ahn et al., 
2006; Altafaj et al., 2001; Shindoh et al., 1996; W. J. Song et al., 1996). Mouse 
models have also been instrumental in parsing discrete, chromosomal regions 
and uncovering genetic pathways that may be amenable to therapeutic targeting 
(P. V. Belichenko et al., 2015; Das et al., 2013; X. Jiang et al., 2015; Olson et al., 
2004; 2007). More recently, bioinformatic approaches have been used to explore 
the transcriptional landscape of DS and highlight candidate genes that may 
contribute to DS phenotypes (Letourneau et al., 2014; Sturgeon, Le, Ahmed, & 
Gardiner, 2012). Our results provide initial clues on the function of several 
uncharacterized HSA21 orthologs that add to established findings. Conclusions 
on the precise mechanism of action of these genes and their possible relevance to 
DS will benefit from more detailed study in C. elegans—including examination of 
possible phenotypes induced by overexpression—as well as further investigation 
using traditional mouse models and human cell line approaches. 
 
MATERIALS AND METHODS 
Strains 
C. elegans were grown on NGM (nematode growth media) agar plates 
seeded with OP50 bacteria at 20° C as described (Brenner, 1974). N2 Bristol 
served as wild type and was also used for outcrossing (Brenner, 1974). For a list 
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of outcrossed strains, refer to APPENDIX F. The following strains were used is 
this study:  BB3 adr-2(gv42) III; CB211 lev-1(e211) IV; CZ18537 zig-10(tm6127) II; 
DR97 unc-26(e345) IV; EK228 mbk-1(pk1389) X; FX1756 pad-2(tm1756) III; FX2021 
rcan-1(tm2021) III; FX2626 Y105E8A.1(tm2626) I; FX2657 nrd-1(tm2657) I; FX3322 
dnsn-1(tm3322) II; FX3565 mtq-2(tm3565) II; FX6706 B0024.15(tm6706) V; FX776 
sod-1(tm776) II; GA503 sod-5(tm1146) II; MT1072 egl-4(n477) IV; NS3026 ikb-
1(nr2027) I; PR678 tax-4(p678) III; PS2627 dgk-1(sy428) X; RB1489 D1037.1(ok1746) 
I; RB2097 set-29(ok2772) I; RB2436 cysl-4(ok3359) V; RB2535 cysl-2(ok3516) II; 
RB870 igcm-1(ok711) X; RB899 cysl-1(ok762) X; RB979 dip-2(ok885) I; VC200 rnt-
1(ok351) I; VC201 itsn-1(ok268) IV; VC3037 mtq-2(ok3740) II; VC40866 pdxk-
1(gk855208) I; VC868 eva-1(ok1133) I; VC943 cle-1(gk421) I; VH860 ncam-1(hd49) X. 
 
Transgenic Strains 
We used standard techniques to generate constructs used to make the 
following transgenic strains:  
 
JPS610 vxEx610 [mtq-2p::mtq-2::mtq-2 UTR + myo-2p::mCherry::unc-54 UTR]; 
mtq-2 (tm3565) 
JPS611 vxEx611 [mtq-2p::mCherry::unc-54 UTR + unc-122p::GFP] 
JPS612 vxEx611 [mtq-2p::mCherry::unc-54 UTR + unc-122p::GFP]; vsIs48 [unc-
17::GFP] 
JPS621 vxEx621 [mtq-2p::mtq-2::mtq-2 UTR + myo-2p::mCherry::unc-54 UTR]; 
mtq-2 (tm3565) 
JPS906 vxEx611 [mtq-2p:mCherry::unc-54 UTR + unc-122p::GFP]; oxIs12 [unc-
47p::GFP + lin-15(+)] 
JPS929 vxEx929 [pdxk-1p::mCherry::unc-54 UTR] 
JPS989 vxEx929 [pdxk-1p::mCherry::unc-54 UTR]; vsIs48 [unc-17::GFP] 
JPS990 vxEx929 [pdxk-1p::mCherry::unc-54 UTR]; oxIs12 [unc-47p::GFP + lin-
15(+)] 
 43 
JPS1044 vxEx1044 [WRM615bF01 + myo-2p::mCherry::unc-54UTR]; 
B0024.15(tm6706) 
JPS1045 vxEx1045 [WRM615bF01 + myo-2p::mCherry::unc-54UTR]; 
B0024.15(tm6706) 
JPS1046 vxEx1046 [WRM061aD07 + myo-2p::mCherry::unc-54UTR]; rnt-1 
(ok351) 
JPS1047 vxEx1047 [WRM061aD07 +myo-2p::mCherry::unc-54UTR]; rnt-1 
(ok351) 
JPS1048 vxEx1048 [pdxk-1p::pdxk-1::pdxk-1UTR; myo-2p::mCherry::unc-54 
UTR]; pdxk-1 (gk855208) 
JPS1049 vxEx1049 [pdxk-1p::pdxk-1::pdxk-1UTR; myo-2p::mCherry::unc-54 
UTR]; pdxk-1 (gk855208) 
JPS1051 vxEx1051 [WRM0611dD03 + myo-2p::mCherry::unc-54UTR]; eva-
1(ok1133) 
JPS1052 vxEx1052 [WRM0611dD03 + myo-2p::mCherry::unc-54UTR]; eva-
1(ok1133) 
JPS1056 vxEx1056 [WRM069bF04 + fat-7p::GFP]; cle-1 (gk421) 
JPS1057 vxEx1057 [WRM069bF04 + fat-7p::GFP]; cle-1 (gk421) 
JPS1058 vxEx1058 [WRM0640bC10 + myo-2p::mCherry::unc-54UTR]; pad-2 
(tm1756) 
JPS1059 vxEx1059 [WRM0640bC10 + myo-2p::mCherry::unc-54UTR]; pad-2 
(tm1756) 
JPS1060 vxEx1060 [WRM0637bA01 + myo-2p::mCherry::unc-54 UTR]; cysl-2 
(ok3516) 
JPS1061 vxEx1061 [WRM0637bA01 + myo-2p::mCherry::unc-54 UTR]; cysl-2 
(ok3516) 
JPS1062 vxEx1062 [WRM0619dG03 + fat-7p::GFP]; ncam-1 (hd49) 
JPS1063 vxEx1063 [WRM0619dG03 + fat-7p::GFP]; ncam-1 (hd49) 
JPS1064 vxEx1064 [cysl-2p::mCherry::unc-54 UTR] 
JPS1065 vxEx1065 [dnsn-1p::mCherry::unc-54 UTR] 
JPS1066 vxEx1066 [WRM0634aG08 + myo-2p::mCherry::unc-54 UTR]; dnsn-1 
(tm3322) 
JPS1067 vxEx1066 [WRM0634aG08 + myo-2p::mCherry::unc-54 UTR]; dnsn-1 
(tm3322) 
 
RNA interference  
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We performed RNAi by feeding as described (Timmons, Court, & Fire, 
2001). All RNAi clones were obtained from SourceBioScience (Nottingham, UK). 
First, RNAi-expressing AMP-resistant bacteria were cultured overnight at 37°C 
with shaking in LB broth containing ampicillin (50 mg/mL) to prevent 
contamination of liquid cultures. The following day, ~100 μL of bacterial liquid 
culture was seeded on NGM plates containing 1-mM isopropyl ß-D-1-
thiogalactopyranoside (IPTG) to induce expression of exogenous RNA by the T7 
promoter. Once a bacterial lawn had sufficiently grown, a mixed age population 
of BZ1272 nre-1(hd20) lin-15b(hd126) double-mutant worms was placed in a 2:1 
mixture of bleach and 1-M NaOH to kill bacteria and post-embryonic worms. 
This strain was selected due to its heightened sensitivity to RNAi in the nervous 
system (Schmitz, Kinge, & Hutter, 2007). Eggs were allowed to hatch and grow 
over the next week at 20⁰C and were observed for the following week. This 
period covers two generations. The first generation of RNAi-treated worms 
experienced post-embryonic effects of the RNAi treatment, while the second 
generation also experienced maternal and pre-embryonic effects. We scored 
viability phenotypes including embryonic lethality, larval lethality, and larval 
arrest and sterility in either the P0 or F1 generation. Control-treated worms were 
fed L440 background-strain bacteria that harbored an empty RNAi vector. 
 
Behavioral assays 
All behavioral assays were performed blind to the genotype or RNAi treatment 
and conducted at room temperature (~20°C). 
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Radial Dispersion Assay: 
To measure radial distance traveled, we placed 5-8 day-one adult worms in the 
center of a 10-cm diameter plate thinly seeded with OP50 bacteria. The distance 
traveled from the center of the plate was measured at 10 minutes (Topalidou et 
al., 2017). A minimum of 30 worms were tested per genotype on at least two 
separate days. 
 
Exploration Assay: 
A single L4-stage worm was placed on a 3.5-cm diameter plate thinly seeded 
with OP50 bacteria and allowed to crawl freely. After 16 hours, we removed the 
worm and used the worm track to count how many of 69 squares the explored 
across. At least 15 worms per genotype were tested on at least two separate days.  
 
Aldicarb Assay:  
Sensitivity to the acetylcholinesterase inhibitor aldicarb was quantified as 
described (Mahoney et al., 2006). At least 25 day-one adult staged worms were 
evaluated per trial. For the aldicarb assay using RNAi-treated worms, worms 
were examined at a single time point (100 minutes) on 1-mM aldicarb and scored 
for paralysis. Trials were performed blind to RNAi treatment and in triplicate for 
two generations (if viable as F1). For the aldicarb assay performed on mutant 
worms, the number of paralyzed worms on 1-mM aldicarb was noted every half 
hour for three hours. A worm was considered paralyzed when it showed neither 
spontaneous movement nor movement in response to being prodded three times 
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on the head and tail with a platinum wire. Assays were repeated a minimum of 
three times. 
 
Levamisole Assay: 
Sensitivity to the acetylcholine receptor agonist levamisole was measured 
as described (Lewis et al., 1980). At least 25 day-one adult-staged worms were 
placed on plates treated with 800-μM levamisole. We scored worms for paralysis 
every ten minutes for one hour. Assays were performed in triplicate. 
 
Pharyngeal Pumping Assay: 
We quantified the pumping rate of day-one staged worms by eye for 
thirty seconds under a stereomicroscope at 100x magnification using a handheld 
counter. A single pump was defined as the backward movement of the grinder 
(Albertson & Thomson, 1976; Raizen, Lee, & Avery, 1995). At least 30 worms per 
genotype were analyzed. 
 
Statistical Analysis: 
For radial dispersion, exploration, and pharyngeal pumping assays, we 
compared values to the wild-type control with a one-way ANOVA with a 
Bonferroni correction to evaluate select comparisons or Dunnett’s test when all 
comparisons were to wild type. Aldicarb and levamisole responses of mutants 
were compared to wild-type control with a two-way ANOVA and a Bonferroni 
correction for select comparisons or Dunnet’s test when all comparisons were to 
wild type. We used GraphPad Prism7 software. To minimize false positives from 
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our screen, we set significance to p < 0.001. For all subsequent assays, significance 
was considered p < 0.05. 
 
Data Availability Statement: 
Strains are available upon request. APPENDIX F contains detailed descriptions 
and sources of all strains used in this study. 
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Figure 2.1: Representation of human 21st chromosome genes in C. elegans. (A) 
HSA21 encodes a conservative estimate of 213 protein-coding genes. Excluding 
the 48 genes predicted to encode keratin on HSA21 (dark gray), over half of the 
remaining 165 genes have predicted orthologs in C. elegans as identified by 
OrthoList. All 85 putative orthologs in worm (light gray and blue) with an 
available RNAi clone were tested in the RNAi viability screen (APPENDIX B, D). 
(B) Representation of InParanoid-predicted orthologs with their human to worm 
relationship (shades of blue). We tested all predicted InParanoid orthologs except 
those within a many-to-many relationship with RNAi for viability and mutants 
for behavioral and aldicarb assays (red). 
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Figure 2.2: Screen for radial dispersion defects. Histograms show the mean 
displacement +/- SEM from start over ten minutes for each worm during a radial 
dispersion assay. (A) Three mutants (green) showed substantial reductions in 
dispersal relative to wild type (black). ***p < 0.001, n > 30. (B) Reductions in 
dispersal were rescued for the cysl-2 and mt-1 mutants (green) by 
extrachromosomal expression of the wild-type genes (blue). Wild-type 
performance shown for comparison (black). *p < 0.05, **p <0.01, ***p <0.001, n > 
30. 
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Figure 2.3: Screen for exploration defects. Histograms show the mean 
percentage of the assay plate traversed (percent of squares entered +/- SEM) by 
individual worms over a 16-h exploration assay. (A) Five mutants (green) covered 
significantly less area than wild type (black). ***p < 0.001, n > 15. (B) Reductions in 
exploration were rescued in the eva-1, C24H12.5, mtq-2(tm3565), and pdxk-1 
mutants (green) by extrachromosomal expression of each of the wild-type genes 
(blue). Wild-type performance shown for comparison (black). *p < 0.05, **p < 0.01, 
***p < 0.001, n >15. 
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Figure 2.4: Screen for pumping defects. Histograms showing mean pharyngeal 
pumps per minute (+/- SD) in the presence of standard bacterial food. (A) Seven 
mutants (green) showed significant defects in pharyngeal pumping relative to 
wild type (black). ***p< 0.001, n > 30. (B) Mutants with pharyngeal pumping 
defects mtq-2(tm3565), pad-2, ncam-1, and cle-1 (green) were rescued by 
extrachromosomal expression of the wild-type genes (blue). We did not observe 
rescue of B0024.15. *p < 0.05, **p < 0.01, ***p < 0.001, n > 30. 
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Figure 2.5: Screen for aldicarb resistance. 
 53 
Figure 2.5: Screen for aldicarb resistance. We measured the full 180-minute time 
course to paralysis for 28 strains including wild type and hypersensitive control 
(dgk-1) in 1-mM aldicarb. Significant difference in paralysis rate was determined 
from WT with a two-way ANOVA using Dunnett’s correction for multiple 
comparisons. No mutants showed significant hypersensitivity. (A) Mean percent 
(+/- SEM) of animals moving on aldicarb over minutes for WT, positive control, 
and mutants that were significantly different from WT: pdxk-1(gk855208), mtq-
2(tm3565), mtq-2(ok3740), and unc-26(e345). p < 0.001, n > 3. (B) Mean percent of 
(+/- SEM) of animals moving on aldicarb at the 180 minute time point for all 
mutants tested including those (green) that were significantly different from WT 
(black). Zero indicates that no animals were moving. 
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Figure 2.6. Response of deletion and putative loss-of-function mutants to 
aldicarb and levamisole.  
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Figure 2.6. Response of deletion and putative loss-of-function mutants to 
aldicarb and levamisole. Time course to paralysis on 1-mM aldicarb or 800-μM 
levamisole for aldicarb resistant mutants identified in screen (n > 3 trials, ~25 
worms per trial). Wild-type controls were assayed in parallel. (A) Two 
independent alleles of mtq-2 (green) displayed significant resistance to aldicarb, p 
< 0.001. Two of two rescue lines of mtq-2(tm3565) (blue) displayed significant 
sensitivity from the mutant background, p < 0.05. (B) Two independent alleles of 
mtq-2 displayed sensitivity to levamisole. (C). pdxk-1(gk855208) displayed 
significant resistance to aldicarb, p < 0.001. One of two rescue lines of pdxk-
1(gk855208) (blue) was significantly improved from the mutant background, p < 
0.01. (D) pdxk-1(gk855208) displayed hypersensitivity to levamisole relative to 
wild type, p < 0.001. (E) unc-26(e345) displayed significant resistance to aldicarb, 
p < 0.001 and (F) hypersensitivity to levamisole, p < 0.001. 
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Figure 2.7. Aldicarb response following RNAi knockdown.  
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Figure 2.7. Aldicarb response following RNAi knockdown.  
Aldicarb resistance of HSA21 orthologs in presence of RNAi treatment. RNAi 
treatment of ncam-1 and pdxk-1 genes (dark gray) resulted in significant 
resistance to paralysis by 1-mM aldicarb relative to the empty vector (L4440) 
negative control (p < 0.001, one-way ANOVA with Dunnet’s post-hoc correction). 
Positive control was egl-21. RNAi of unc-26 caused no change in sensitivity (not 
shown). RNAi-treatments were tested in triplicate over two generations when 
viable (n = 3-6 trials). 
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Figure 2.8. Expression pattern of select genes.  
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Figure 2.8. Expression pattern of select genes. Fluorescent micrographs of all 
HSA21 ortholog hits for which expression patterns were unknown. (A1-3) A 
transcriptional reporter for mtq-2 expressed mCherry throughout the adult 
nervous system including in head (A3). Bright field image shown in A1 for 
reference. Scale bar, 100 μm. Dual color images show co-expression of mtq-2 
reporter in cholinergic (arrowheads, A4) but not in GABAergic neurons (A5) in the 
ventral nerve cord. Scale bar, 50 μm. (B1-3) A transcriptional reporter for pdxk-1 
expressed mCherry throughout the adult nervous system including in head (B3). 
Bright field image shown in B1 for reference. Scale bar, 100 μm. Dual color 
images show co-expression of pdxk-1 reporter in GABAergic neurons (B5) but not 
cholinergic neurons (B4) in the ventral nerve cord. Scale bar, 50 μm. (C) A 
transcriptional reporter for dnsn-1 expressed mCherry widely in developing 
embryo. Scale bar, 50 μm. (D) A transcriptional reporter for cysl-2 expressed 
mCherry throughout body wall and vulval muscle. Scale bar, 100 μm. 
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Behaviors Expression 
 
Table 2.1. Summary of HSA21 gene orthologs required for normal behaviors in 
C. elegans 
 indicates the direction of changes that significantly differ from wild type (p < 
0.001, one-way ANOVA) 
RIC (Resistant to Inhibitors of Cholinesterase) indicates mutants with significant 
resistance to aldicarb vs wild type (p < 0.001, two-way ANOVA) 
✓ indicates tissue(s) in which the gene is expressed. Data were derived from 
WormBase (Lee et al., 2018). Underline signifies results found in this study. 
* HSA21 gene and mouse gene orthologs derived from InParanoid (Sonnhammer 
& Östlund, 2015). 
‡ Mouse viability data derived from the Mouse Genome Informatics database 
(Blake et al., 2017).  
Specific citations are as follows: 1(Watanabe et al., 1995), 2(P. Liu et al., 2010), 
3(Okuda, Van Deursen, Hiebert, Grosveld, & Downing, 1996), 4(Cremona et al., 
1999) 
  
             
cle-1 Collagen 
  
 
 
 ✓ 
  
COL18A1 Col18a1 viable 
cysl-2 Cysteine synthase 
 
   
 
 
✓ ✓ CBS Cbs postnatal lethal1 
dnsn-1 Novel 
 
 
  
 
  
✓ DONSON Donson viable 
eva-1 Slit receptor 
 
 
  
 ✓ 
  
EVA1C Eva1c viable 
mtq-2 Glutamine 
methyltransferase 
 
  RIC  ✓ 
  
N6AMT1 N6amt1 embryonic 
lethal2 
ncam-1 Neural cell adhesion 
molecule 
  
 
 
 ✓ 
  
NCAM2 Ncam2 viable 
pad-2 O-fucosyltransferase      ✓ ✓  POFUT2 Pofut2 preweaning 
lethal 
pdxk-1 Pyridoxal kinase 
 
 
 
RIC  ✓ 
  
PDXK Pdxk preweaning 
lethal 
rnt-1 Runx transcription 
factor 
 
   
 ✓ ✓ ✓ RUNX1 Runx1 embryonic 
lethal3 
unc-26 Synaptojanin    RIC  ✓ 
  
SYNJ1 Synj1 perinatal lethal4 
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CHAPTER THREE 
 
CHARACTERIZATION OF MTQ-2 
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ABSTRACT 
Recently we identified mtq-2 as a novel gene required for normal nervous system 
function and synaptic transmission in a screen of human 21st chromosome 
orthologs in C. elegans. Here, we use behavioral genetics and confocal microscopy 
to functionally characterize mtq-2, which, encodes a well-conserved ortholog of 
human N6AMT1, a predicted glutamine methyltransferase. The phenotypes of 
mtq-2 mutants are reminiscent of Gα signaling mutants, which prompted us to 
investigate potential interactions among genes in this signaling pathway. We 
found that mutants of the GαO subunit GOA-1 strongly suppressed mtq-2 loss-of-
function phenotypes, suggesting that mtq-2 may act upstream of or in 
conjunction with goa-1 to mediate synaptic vesicle release. As a novel molecular 
modulator of neurotransmission, mtq-2 may contribute to neurological 
phenotypes when overexpressed in Down syndrome and should be prioritized 
for further study. 
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INTRODUCTION 
 Faithful signal transduction at the chemical synapse requires precise 
spatiotemporal coordination of hundreds of molecules. Proteins involved in 
synaptic vesicle release perform diverse functions, from comprising the core 
synaptic vesicle machinery to modulating levels of second messenger molecules. 
Among the latter class, heterotrimeric G proteins have been among the most 
intensively studied. In addition to regulating levels of second messenger 
molecules at the synapse, G proteins are also involved in many aspects of 
development. With such myriad and important functions, it is unsurprising that 
G proteins—the Gα subunit in particular—are subject to many forms of 
regulation. Gα proteins are molecular switches, activated, or “on” in the presence 
of GTP and inactivated, or “off,” when bound to GDP. Thus, regulation of G 
proteins often revolves around control of the GTP or GDP bound state. There are 
three broad categories of proteins that regulate the duration of the Gα signal: 1) 
RGS (regulators of G protein signaling) proteins rapidly terminate the Gα signal 
by promoting the hydrolysis of GTP for GDP; 2) GEFs (guanine nucleotide 
exchange factors) stimulate the exchange of GDP for GTP thereby activating the 
Gα protein; and 3) GDIs (guanine nucleotide dissociation inhibitors) block the 
exchange of GDP for GTP and lock the Gα protein in its inactive state (Schmidt & 
Hall, 2002). Finally, heterotrimeric Gα proteins can be post-translationally 
modified. For instance, lipidation of select residues on Gα proteins encourages 
appropriate localization to microdomains within the cell (Schmidt & Hall, 2002). 
 In a previous screen of human 21st chromosome orthologs in C. elegans, we 
identified a novel gene, mtq-2 (methyltransferase modifying glutamine (Q), required 
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for multiple behaviors and normal synaptic signaling (Table 3.1). Though this 
gene is well-conserved, its functional role is unclear. Mice lacking the 
orthologous gene, N6amt1, die very early in embryonic development, precluding 
further study (P. Liu et al., 2010). In contrast, C. elegans mtq-2 mutants are viable. 
 By homology, mtq-2 is a glutamine methyltransferase. In general, glutamine 
methylation is less well-characterized than methylation of arginine or lysine 
residues; nevertheless, non-histone glutamine methylation does occur on 
translation termination factors and ribosomal proteins (Polevoda & Sherman, 
2007). Direct evidence for glutamine methylation by MTQ-2  on class I translation 
termination factors (ETF1 in eukaryotes and prmC in bacteria) has been shown in 
E. coli, yeast, and mouse (P. Liu et al., 2010; Nakahigashi et al., 2002; Polevoda et 
al., 2006). Biochemically, methylation of the target glutamine on the release factor 
is associated with increased efficiency of translation termination either by 
directly participating in hydrolysis of the tRNA-peptide bond or by increasing 
the affinity of the release factor to the ribosome (Dinçbas-Renqvist et al., 2000; 
Korostelev, Zhu, Asahara, & Noller, 2010; H. Song et al., 2000). More recently, a 
minimal recognition motif for MTQ-2 was discovered, GQX3R , and the MTQ-2 
complex was found to methylate hundreds of other substrates in vitro (Kusevic et 
al., 2016). This raises the possibility that MTQ-2 may have targets other than the 
translation termination factor. 
 The biochemical evidence that MTQ-2 may bind additional substrates, 
coupled with the behavioral phenotype of mtq-2 we previously reported (Table 
3.1), suggested that mtq-2 may be interacting with one or more proteins already 
known to mediate synaptic signaling in worm. In particular, mtq-2 mutants were 
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phenotypically reminiscent of mutants involved in Gα signaling. Moreover, 
almost all C. elegans Gα proteins contain the mtq-2 minimal recognition motif, 
and this motif is conserved across diverse species in GαO (Figure 3.1). Here we 
show that mtq-2 is required for normal nervous system function, normal 
excitatory neurotransmission, and that it functions, specifically, in cholinergic 
neurons to mediate its effects. Finally, we provide evidence of a potential genetic 
interaction between mtq-2 and goa-1 that future research should seek to confirm. 
 
RESULTS 
mtq-2 functions in cholinergic neurons to mediate neurotransmission 
 We initially identified mtq-2 as a gene required for several behaviors 
dependent on proper nervous system function (Table 3.1). Further, we found 
that a transcriptional reporter of mtq-2 expressed robustly and exclusively in 
neurons and, specifically, cholinergic neurons. Given the dependency of many of 
the behaviors on cholinergic function and the expression pattern of mtq-2, we 
tested whether a cholinergic promoter driving mtq-2 was sufficient to restore 
function of the aldicarb response to wild-type levels. We found that cholinergic 
expression of mtq-2 in a null background restored aldicarb sensitivity to wild-
type levels (Figure 3.2). This suggests that mtq-2 functions largely in cholinergic 
neurons to mediate neurotransmission. This interpretation is strengthened by 
our previous finding that mtq-2 showed wild-type sensitivity to the nAChr 
agonist levamisole (Nordquist et al., 2018) 
 
MTQ-2 localizes to cholinergic synapses and processes 
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 To determine the subcellular localization of MTQ-2, we attached mCherry 
to the C-terminus of genomic MTQ-2, while preserving the endogenous 5’ and 3’ 
regulatory elements. We found that MTQ-2::mCherry localized to cholinergic 
axons and presynapses indicating that MTQ-2 may play more of a direct role in 
synaptic vesicle release (Figure 3.3). To ensure that the fluorescent tag was not 
disrupting the function of the native protein, we performed an aldicarb assay 
and observed full rescue of the loss-of-function phenotypes with MTQ-
2::mCherry (Figure 3.3). Together, these findings are consistent with a role for 
mtq-2 in regulating synaptic release at cholinergic synapses. 
 
MTQ-2 does not strongly affect the development of synapses 
 Deficiencies in cholinergic release could be caused by a failure of 
cholinergic synaptic formation or localization or by decreased release in existing 
cholinergic synapses (Hiley, McMullan, & Nurrish, 2006). We were curious if 
mtq-2 caused deficiencies in synaptic vesicle release due to fewer synapses or due 
to deficiencies in release at existing synapses. To address the former point, we 
examined the number, distribution, and relative fluorescent intensity of 
cholinergic synapses (Klassen & Shen, 2007). In worm, synapses form en passant 
along the dorsal cord axon in a highly-stereotyped manner and can be visualized 
with a synaptic vesicle associated marker (Klassen & Shen, 2007). Fluorescent 
reporters provide a readily observable measure of synapse development and/or 
functional state. Each punctum corresponds to a single neuromuscular junction 
(Jin, Jorgensen, Hartwieg, & Horvitz, 1999). Further, electron microscopy 
experiments have revealed a correlation between the relative intensity of the 
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synaptic vesicle reporter and the number of synaptic vesicles (Richmond & 
Jorgensen, 1999; Weimer et al., 2003). 
 As a model of synaptic number and intensity, we examined synaptic puncta 
in the cholinergic DA9 motoneuron. The DA9 neuron is one of the most 
posteriorly located neurons in the worm. DA9 extends a dendritic process 
anteriorly along the ventral cord and sends a commissural axon to the dorsal 
cord (Figure 3.4). Adult wild-type animals have around 25 synapses along the 
length of the axonal dorsal cord. We found no differences between mtq-2 mutants 
and the control strain in the number of cholinergic synapses, their distribution 
along the dorsal cord axon, or their relative fluorescent intensity (Figure 3.5). In 
mtq-2 mutants, we did observe ectopic puncta in the dendrite; however, this 
phenotype was of low penetrance (1 of 10 animals), and we did not pursue it 
further. These results most plausibly suggest that mtq-2 may affect release 
dynamics of neurotransmitter from preexisting synapses, yet we cannot 
conclusively rule out a developmental role. 
 
mtq-2 may act upstream of or in conjunction with goa-1 
 The phenotypes of mtq-2 are similar to those of other mutants involved in 
Gα signaling and prompted us to explore whether mtq-2 was interacting with 
genes in these pathways to regulate synaptic vesicle release. There are three main 
classes of heterotrimeric G proteins known to be involved in neurotransmitter 
release: GαO, GαQ, and GαS; all of which are represented by one ortholog of each 
class in worm (Bastiani & Mendel, 2006; Brown & Sihra, 2008). Both gsa-1 (GαS) 
and egl-30 (GαQ) inhibit neurotransmitter release, while goa-1 (GαO) promotes 
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neurotransmitter release, primarily through inhibition of egl-30 (GαQ) (Figure 
3.7).  
 Worm has been a particularly informative system for elucidating the 
function of G proteins; in part, because of the readily observable phenotypes of 
the Gα mutants (Koelle, 2016). Loss of function mutants of Gαs and Gαq are 
characteristically sluggish, egg retentive, and resistant to the acetylcholinesterase 
inhibitor aldicarb. Loss of function mutants of GαO display the converse 
phenotypes: locomotor hyperactivity, constitutive egg laying, and 
hypersensitivity to the acetylcholinesterase inhibitor aldicarb (Koelle, 2016).  
 Given the opposite loss-of-function phenotypes for mutants of goa-1 (GαO) 
and mtq-2, we focused on goa-1 for epistasis analysis. If mtq-2 functions upstream 
of goa-1, we would expect the double mutant mtq-2; goa-1 to show the 
phenotypes of the goa-1 single mutant (i.e. aldicarb hypersensitivity and 
constitutive egg laying). We found that the double mutant of mtq-2; goa-1 
strikingly suppressed the mtq-2 phenotypes suggesting that mtq-2 functions 
upstream of or in conjunction with goa-1 (Figure 3.6). 
 goa-1 mediates synaptic vesicle release via two known pathways: a dgk-1 
(diacylglycerol kinase) dependent pathway and an eat-16 (RGS) dependent 
pathway.  Importantly, both dgk-1 and eat-16 were found to function downstream 
of goa-1 in a genetic screen for suppressors of activated goa-1 (Hajdu-Cronin, 
Chen, Patikoglou, Koelle, & Sternberg, 1999). It is currently unknown if goa-1 
directly binds dgk-1 and eat-16 or if intermediate targets exist; biochemical 
studies have yet to confirm these genetic relationships (Bastiani & Mendel, 2006). 
Nevertheless, dgk-1 assumes a critical role at the synapse. A kinase, dgk-1 
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phosphorylates the second messenger molecule DAG (diacylglycerol), thereby 
converting it to PA (phosphatidic acid). Levels of DAG within the cell directly 
correlate to levels of synaptic vesicle release, and, accordingly, loss of function 
mutants of dgk-1 are extremely hypersensitive to the paralytic effects of aldicarb 
(van Swinderen et al., 2001). We examined the time course to paralysis for mtq-2; 
dgk-1 double mutants and found that they displayed intermediary egg-laying 
and aldicarb response phenotypes of dgk-1 and mtq-2 single mutants. 
Qualitatively, mtq-2; dgk-1 double mutants also displayed a mixture of 
phenotypes from the mtq-2 and dgk-1 single mutants: their crawl speed was 
intermediate to the single mutants, yet they moved with the characteristic 
jerkiness of dgk-1 (Fig 3.6). These results most likely suggest that mtq-2 acts 
upstream of goa-1 to mediate SV release via diacylglycerol kinase dgk-1 
independent genetic pathway. 
 
DISCUSSION 
 Here we characterize a novel gene, mtq-2, which we found to mediate 
neurotransmitter release from cholinergic neurons in C. elegans. We further show 
that loss of mtq-2 predominantly disrupts the function of preexisting synapses in 
the adult animal. Finally, we discovered that loss of goa-1 strikingly suppressed 
mtq-2 phenotypes, which suggests that mtq-2 functions upstream of or in 
conjunction with goa-1 to regulate synaptic vesicle release from cholinergic 
neurons. 
 The presence and high conservation of the recently discovered mtq-2 
minimal recognition motif among Gα proteins—including GOA-1 (GαΟ)—is 
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intriguing and suggests that MTQ-2 may regulate GOA-1 activity by direct 
methylation. On the human ortholog of goa-1 (GNAO1), the target glutamine 
(Q205) resides within a highly conserved nucleotide binding pocket (Mendel et 
al., 1995). Previous studies have revealed that a Q205L substitution constitutively 
activates GαO, presumably by blocking GTPase activity and locking the Gα 
protein in its activated state (Slepak, Wilkie, & Simon, 1993; Strittmatter, 
Fishman, & Zhu, 1994). It is tempting to speculate that methylation of Q205 may 
somehow interfere with GDP to GTP exchange; however, additional research 
will first need to determine the presence of methylglutamine on GαO. 
 In summary, our findings provide initial support for a novel MTQ-2-
mediated mechanism for the influence of synaptic function. Further research will 
be necessary to evaluate whether MTQ-2 methylation of Gα proteins underlies 
this potentially conserved pathway. 
 
 
MATERIALS AND METHODS 
Strains 
 C. elegans were grown on NGM (nematode growth media) agar plates 
seeded with OP50 bacteria at 20 °C as described (Brenner, 1974). N2 Bristol was 
wild type and was also used for outcrossing. The following mutant strains were 
used is this study:  JT734 goa-1(sa734) I; VC3037 mtq-2(ok3740) II; FX3565 mtq-
2(tm3565) II; PS2627 dgk-1(sy428) X; JPS1016 mtq-2(ok3740) II; goa-1(sa734) I; 
JPS1014 mtq-2(ok3740 II); dgk-1(sy428) X. 
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Transgenic strains  
 The following transgenic strains were used in this study: wyIs85 (Pitr-1 
pB::GFP:: rab-3) was used as a reporter and to generate JPS787 (mtq-2(ok3740 II; 
wyIs85 (Pitr-1 pB::GFP:: rab-3)). The deletion allele mtq-2(ok3740) II was confirmed 
with standard genotyping procedures. The following strains express mtq-2 under 
the unc-17 promoter: JPS1080 vxEx1080[Punc-17::MTQ-2::mtq-2UTR, pmyo-
2::mCherry]; mtq-2(ok3740)II, JPS1081 vxEx1081[Punc-17::MTQ-2::mtq-2UTR, pmyo-
2::mCherry]; mtq-2(ok3740)II, JPS1082 vxEx1082[Punc-17::MTQ-2::mtq-2UTR, pmyo-
2::mCherry]; mtq-2(ok3740)II, JPS1083 vxEx1083[Punc-17::MTQ-2::mtq-2UTR, pmyo-
2::mCherry]; mtq-2(ok3740)II. To generate strains expressing MTQ-2 tissue-
specifically, we first subcloned MTQ-2 into a pCRTM-Blunt II-TOPO® vector and 
confirmed the absence of mutations by sequencing. We used SphI and BamHI to 
pull out the unc-17 promoter from the PT63 plasmid and used Gibson 
Assembly® to stitch the unc-17 promoter and MTQ-2 gene and 3’ UTR fragments 
together. The following strain is mCherry tagged MTQ-2: JPS836 vxEx836[pmtq-
2::MTQ-2::mCherry::mtq-2 UTR, coel::GFP]; mtq-2(ok3740) II. We also used Gibson 
Assembly® to attach mCherry to the C-terminus of MTQ-2. The mCherry 
fluorophore was derived from pCFJ90.  
 
Aldicarb assay 
 Aldicarb assay were performed as described in (Mahoney et al., 2006). We 
first prepared 1mM aldicarb plates by dissolving an aldicarb stock solution into 
cooled, standard NGM agar. Plates were left to dry on the bench overnight 
before placing in a 4°C incubator. On the day of the assay, plates were removed 
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an allowed to come to room temperature for about 30 minutes. 25-30 staged day 
one adults were transferred from a seeded OP50 plate to the center of the 
aldicarb treated plate. We transferred animals in the presence of food to 
encourage animals to remain in the center of the plate. During the first hour of 
the assay, animals were gently moved back to the center of the plate to facilitate 
scoring. Each half hour, an individual animal was observed for spontaneous 
movement on an Olympus SZX16 Stereo Microscope. If the animal had ceased 
spontaneous movement, we gently prodded its head and tail three times to 
determine if the animals responded to evoked touch. Animals were considered 
paralyzed when no movement was observed following gentle prodding. 
 
Egg retention assay 
The assay for egg retention was performed essentially as described in 
(Hart, 2006). 24 hours (± 1 hour) before the start of the experiment, late L4 
animals were transferred to a new, seeded plate and allowed to develop to 
adulthood at room temperature. The day of the experiment, a 10% bleach 
solution was freshly prepared and passed through a syringe filter (VWR 
International 25mm syringe filter with 0.2 μm nylon membrane, 28145-147) to 
remove debris. 50 μL was pipetted into individual wells of a 96 well plate. A 
single animal was picked into a single well and incubated until its cuticle was 
well-dissolved (8-20 minutes). The number of eggs per animal was counted on an 
Olympus SZX16 Stereo Microscope. Only animals with fully dissolved cuticles 
were scored. Care was taken to ensure each animal was positioned in the center 
of the well. Any animal not positioned in the center of the well was not scored 
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due to the difficulty of accurately resolving egg number on the edges of the well. 
Assays were performed blind and repeated on at least three separate days. 
 
Confocal microscopy 
Staged day one adult animals were placed on an agarose pad and 
immobilized with NaN3. All animals were imaged within 45 minutes of 
mounting. We used a Leica Plan-Apochromat 63X/1.4 objective on a Leica 
DM6000 CFS confocal microscope to collect z-stacks of the dorsal nerve cord. For 
all experiments, FIJI was used to create maximum z-stack projections of the 
dorsal cord of each animal. For experiments measuring synapse localization, 
puncta count, and relative fluorescent intensity, gain and offset settings were 
invariant. To determine puncta count, we set a threshold based on the wild-type 
reporter strain and used the “Analyze Particles” plug-in in FIJI. To determine 
relative fluorescent intensity along the nerve cord, we isolated ten dorsal nerve 
cords from each animal. We defined the bend at which the commissural axon 
curves into the dorsal cord as the starting point (i.e. 0 on x-axis) and extended s 
line 175 μm out. We used the “Straighten” plug-in in FIJI to straighten the dorsal 
nerve cords and the “Plot Profile” plug-in to generate fluorescent intensity as a 
function of distance for the composite images.  
 
Statistical analysis 
For radial dispersion, exploration, pharyngeal pumping, and egg 
retention assays, we compared values to the wild-type control with a one-way 
ANOVA with a Bonferroni correction to evaluate select comparisons or 
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Dunnett’s test when all comparisons were to wild type. Aldicarb responses of 
mutants were compared to wild-type control with a two-way ANOVA and a 
Bonferroni correction for select comparisons or Dunnet’s test when all 
comparisons were to wild type. We used GraphPad Prism7 software. 
Significance was considered p < 0.05. 
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Genotype 
Aldicarb 
response1, 2 
Levamisole 
response1 Eggs in utero2 
N2 WT WT 13 ± 0.4 
mtq-2(tm3565) RIC WT 20 ± 1.4 
mtq-2(tm3565); mtq-2(+) WT - - 
mtq-2(ok3740) RIC WT 22 ± 0.7 
mtq-2(ok3740); mtq-2(+) WT - 16 ± 1 
 
Table 3.1. Summary of phenotypes of mtq-2  
Dashes indicate no data. 
1 indicates data previously published in (Nordquist et al., 2018).  
2 indicates data collected in this study 
Mean egg in utero presented ± s.e.m. JPS837 is rescue strain for mtq-2(ok3740); 
mtq-2(+) 
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Figure 3.1. Conservation of mtq-2 minimal recognition motif in Gα proteins.   
A. Alignment of all Gα proteins in C. elegans (Bastiani & Mendel, 2006). The mtq-2 
minimal recognition motif (Kusevic et al., 2016) is highlighted in red. B. 
Alignment GαO across species. 
 
 77 
 
 
Figure 3.2. mtq-2 functions in cholinergic neurons to mediate aldicarb 
response 
Shown here is the (A) full time course to paralysis in the presence of 1-mM 
aldicarb and (B) response to aldicarb at 180 minutes plotted for clarity. Mean 
percent of responsive animals are plotted. Error bars indicate s.e.m. Trials for all 
strains were performed at least three times.  
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Figure 3.3. MTQ-2::mCherry localizes to cholinergic synapses 
A. Confocal micrographs showing RAB-3::GFP, MTQ-2::mCherry, and merged 
synapses of the cholinergic DA9 neuron along the dorsal cord. All animals are 
oriented such that left is anterior and up is dorsal. Scale bar, 10 μm. B. mCherry 
tagged MTQ-2 rescues aldicarb response of mtq-2(ok3740) indicating that 
mCherry does not interfere with the normal function of the protein. Mean 
percent of responsive animals shown. Error bars are s.e.m.  At least five trials 
were performed for each strain. 
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Figure 3.4. Location of DA9 neuron and axonal puncta 
A. Red box indicates location of the DA9 cholinergic neuron in the tail of the 
animal. B. Enlargement of area circumscribed in A. Numbers refer to other 
anatomical landmarks: 1) VA12 neuron, 2) anus, 3) gut. The soma and axon of 
DA9 is shown in blue. The DA9 dendrite is shown in green. The stereotyped 
location of DA9 synaptic puncta are shown as red dots along the dorsal cord. 
Bracket indicates asynaptic region. From (Klassen & Shen, 2007) 
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Figure 3.5. mtq-2 does not alter synaptic vesicle localization or fluorescence 
intensity in the DA9 motoneuron. 
 81 
Figure 3.5. mtq-2 does not alter synaptic vesicle localization or fluorescence 
intensity in the DA9 motoneuron. A. Confocal micrographs of ten straightened 
and aligned dorsal cords from wild-type animals and mtq-2(ok3740) animals. All 
animals are oriented such that let is anterior and up is dorsal. Scale bar, 10 μm. B. 
Quantification of fluorescence intensity for composite images. Wild-type animals 
are shown in purple and mtq-2(ok3740) in green. Dotted lines represented actual 
values and solid lines a 10 μm sliding average. C. Average number of synaptic 
puncta per genotype. There are no differences (p > 0.05) in the mean number of 
synaptic puncta between wild-type and mtq-2 (ok3740). Error bars indicate s.e.m. 
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Figure 3.6. mtq-2 may regulate neurotransmitter release and egg laying via 
goa-1 (GαO) 
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Figure 3.6. mtq-2 may regulate neurotransmitter release and egg laying via 
goa-1 (GαO). A. Micrographs comparing visible phenotypes of wild-type, mtq-
2(ok3740), goa-1, mtq-2; goa-1, dgk-1, and mtq-2; dgk-1. Scale bar is 100 μm. Note 
that mtq-2 mutants are bloated with eggs (in addition to being aldicarb resistant 
and having lower amplitude body bends). In contrast to goa-1 mutants do not 
retain eggs. Double mutants of mtq-2; goa-1 appear as the goa-1 single mutant. B-
C. Shown here is the time course to paralysis in the presence of 1-mM aldicarb. 
Mean percent of responsive animals are plotted. Error bars indicate s.e.m. Trials 
for all strains were performed at least four times. B. Mutants for mtq-2 are 
moderately resistant to the paralytic effects of aldicarb while goa-1 mutants are 
strongly hypersensitive. Double mutants of mtq-2; goa-1 display a time course to 
paralysis indistinguishable from the goa-1 single mutants. C. Mutants for mtq-2 
are moderately resistant to the paralytic effects of aldicarb while dgk-1 mutants 
are strongly hypersensitive. Double mutants of mtq-2; dgk-1 display a time course 
to paralysis intermediary to mtq-2 and dgk-1 single mutants. D-E. Shown is the 
mean number of eggs retained in the uterus of staged day one animals (L4 +- 24). 
Error bars indicate s.e.m. At least thrity animals per strain were scored. D. mtq-2 
mutants retain eggs while goa-1 mutants constitutively lay eggs. Double mutants 
of mtq-2; goa-1 appear as the goa-1 single mutant. E. Double mutants of mtq-2; 
dgk-1 appear to have a phenotype intermediary to the mtq-2 and dgk-1 single 
mutants. 
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Figure 3.7. Proposed model for regulation of synaptic vesicle release by mtq-2. 
Green boxes indicate C. elegans proteins known to stimulate ACh release. Red 
boxes indicate proteins known to inhibit ACh release. Gray boxes show second 
messenger molecules. Solid lines and arrows indicate direct genetic interactions 
while dashed lines indicate the possibility of intermediates. Double blue arrows 
indicate the presence of downstream intermediates. Our data suggest MTQ-2 
acts upstream of GOA-1 to inhibit the function of GOA-1. Research from other 
laboratories has determined all other downstream effectors of GOA-1. Adapted 
from (Bastiani & Mendel, 2006). 
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CONCLUDING REMARKS AND FUTURE DIRECTIONS 
In this thesis I functionally characterized all human 21st chromosome 
orthologs in C. elegans. The promise of this work lies in its potential. Candidate 
genes I identified are of immediate interest to Down syndrome research efforts 
and may also be useful for understanding phenotypes associated with genomic 
copy-number variation (CNV). Of the ten genes, I identified as required for 
normal behaviors in worm, six are inviable in mouse. This finding inadvertently 
highlights the importance of relying on multiple animal models to elucidate the 
in vivo function of genes.  
 
Implications of Functional Screen of HSA21 Orthologs 
Positive genes that came out of my screen can be grouped into the 
following categories: 1) genes with previously established links to the nervous 
system, 2) genes well-studied outside of the context of the nervous system, and 
3) poorly characterized or novel genes weakly linked to the nervous system if at 
all.  
As expected, functional screening identified genes with established links 
to nervous system function in both worm and mammal. Genes in this category 
include: eva-1 (EVA1C), ncam-1 (NCAM2), and unc-26 (SYNJ). Two of these genes, 
eva-1 (EVA1C) and ncam-1 (NCAM2), are involved in axon guidance in worm, 
while unc-26 (SYNJ) mediates synaptic vesicle release. In mouse, EVA1C, 
NCAM2, and SYNJ function similarly to their worm orthologs. EVA1C, a Slit 
receptor, has been proposed to mediate mammalian axon guidance on the basis 
of its axonal expression pattern in the developing brain, and NCAM2, a neural 
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cell adhesion molecule, has been shown to stimulate neurite branching in mouse 
cortical neurons (James, Foster, Key, & Beverdam, 2013; Sheng, Leshchyns'ka, & 
Sytnyk, 2015). Finally, SYNJ1, synaptojanin, mediates synaptic vesicle recycling 
in mammal as it does in worm (Cremona et al., 1999; Harris et al., 2000). Of note, 
both eva-1 and unc-26 were both identified and initially characterized in C. elegans 
(Brenner, 1974; Fujisawa et al., 2007). These findings support the use of C. elegans 
to guide research in mammals and demonstrate the predictive value of functions 
ascribed to C. elegans genes.  
I identified a novel neuronal phenotype for, rnt-1 (RUNX1), a 
transcription factor well-studied in worm for its role in general development, 
including cell proliferation and development of the male tail (Hajduskova et al., 
2009; Nimmo et al., 2005). More recent research in mammal has revealed that 
RUNX1 plays an essential role in the developing nervous system (Wang & 
Stifani, 2017). The radial dispersion assay I used to detect locomotor phenotypes 
of rnt-1 mutants is quick, straightforward, and ideal for a forward genetic screen 
in the future.  
My screen also unearthed three genes that are poorly characterized with 
respect to the nervous system: dnsn-1 (DONSON), pdxk-1 (PDXK), and mtq-2 
(N6AMT1). I further characterized mtq-2, which I will discuss in a later section; 
however, all three of genes deserve more detailed analysis to determine their 
precise function and mechanism of action.  
I found that dnsn-1 mutants displayed an extended dwelling phenotype, 
suggestive of deficits to sensory and/ or motor neuron function or development. 
Additionally, I found that a transcriptional reporter of dnsn-1 expressed only 
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during the egg stage, further hinting at a possible role in development. The 
mammalian ortholog of dnsn-1, DONSON, was only recently described. Through 
whole-exome sequencing of patients with microcephalic dwarfism, Reynolds 
found that mutations in DONSON underlay the disorder (Reynolds et al., 2017). 
Prior to the Reynolds study, Drosophila researchers had already characterized the 
fly ortholog of DONSON, humpty-dumpty (hd). Hd mutants (as their name 
divertingly suggests) have very thin egg shells, a phenotype characteristic of 
genes involved in DNA replication (Bandura et al., 2005). In fly, Bandura 
confirmed that hd was essential for ovarian DNA replication and cell 
proliferation during brain development (Bandura et al., 2005). Informed by the 
fly phenotypes, Reynolds found that human DONSON also functioned in DNA 
replication as a novel replication fork protein (Reynolds et al., 2017).  
 In my screen of HSA21 orthologs, I also showed that pdxk-1 (PDXK) 
mutants were defective in several behaviors, including appropriate response to 
the acetylcholinesterase inhibitor aldicarb. The biochemical function of PDXK 
has been worked out: PDXK phosphorylates vitamin B6, converting it to PLP 
(pyridoxal-5’-phosphate), a key cofactor in the metabolism of hundreds of 
enzymatic reactions, including synthesis of neurotransmitters (Cao et al., 2006; 
Shetty & Gaitonde, 1980). The behavioral role of PDXK in mammal is less clear, 
probably, in part, because loss of Pdxk is pre-weaning lethal in mouse (Blake et 
al., 2017). In worm, I found that RNAi knockdown of pdxk-1 caused aldicarb 
resistance—a compelling result; however, there were no characterized loss-of-
function or deletion alleles. I identified three conserved residues on pdxk-1 
corresponding to uncharacterized point mutations in alleles from the Million 
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Mutation Project (MMP) (Figure 4.1). The Million Mutation Project is a 
collaborative effort in which C. elegans strains bearing many mutations are 
generated and mapped with whole-genome sequencing. I examined the 
phenotypes of all three MMP alleles. The strain harboring a M271I mutation 
(VC20794) appeared severely sick and I was unable to outcross it despite 
repeated attempts. I did not pursue study of this strain further. The second 
strain, VC40336, harboring a T155I mutation, exhibited a wild-type aldicarb 
response. The third strain, VC40866, containing an E148K mutation, displayed 
aldicarb resistance and behavioral deficits, which were weakly rescued with 
extrachromosomal expression of wild-type pdxk-1 (Figure 2.6). I had difficulty 
generating viable animals carrying an extrachromosomal array of pdxk-1. I was 
only able to create strains carrying pdxk-1 as an array by injecting a very low 
concentration of DNA (1 ng/ μl), which, possibly, suggests dose-sensitivity of the 
gene. As the human ortholog of pdxk-1 is also predicted to be dose-sensitive 
(Antonarakis, 2016), further examination of this gene is merited. Ideally, CRISPR-
based methods could be used to generate a null allele, which—if inviable—could 
be maintained as a heterozygote. Finally, the GABA neuron specific expression 
pattern I observed with a transcriptional reporter of pdxk-1 was unexpected and, 
frankly, odd. C. elegans mutants defective in GABA signaling typically display 
several distinctive phenotypes (i.e. altered defecation cycle, abnormal response to 
mechanical stimuli), which I did not observe in pdxk-1 mutants (McIntire, 
Jorgensen, Kaplan, & Horvitz, 1993). Due to the compactness of the worm’s 
nervous system, deficiencies in GABA signaling can also cause an altered 
response to aldicarb (Vashlishan et al., 2008); yet, I would encourage anyone 
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wishing to pursue this gene to attempt to tag the protein with CRISPR-based 
techniques to confirm the expression pattern.  
In addition to the novel genes I identified in my screen, there are 
additional orthologs that are inviable in worm and were not examined. Some of 
these genes are already known to express in the nervous system, including atp-3 
(ATP5O) and ubc-14 (UBE2G2) (Table 4.1). It would be interesting to characterize 
these genes following mosaic knockdown in neurons, which could suggest a 
mechanism of action otherwise obscured. 
Finally, overexpression techniques can be used to further characterize 
HSA21 orthologs in worm. I examined overexpression phenotypes of two 
candidate genes: pdxk-1 and mtq-2. Overexpression of mtq-2 resulted in 
pronounced sterility, which I will discuss in the next section. As previously 
noted, I had difficulty generating animals bearing pdxk-1 as an 
extrachromosomal array and successfully created transformants only by injecting 
a very low concentration (1ng/ μl) of DNA. Among these transformants 
overexpressing pdxk-1 at low concentration, I did not observe any obvious 
phenotypes. When dealing with extrachromosomal arrays, the following truism 
in biology especially applies: positive results are informative; negative results are 
far less telling. In general, C. elegans appear to be fairly tolerant to physiologically 
relevant increases in the dosage of wild-type genes (Hodgkin, 2005). Multi-copy 
array overexpression of certain genes, however, is sometimes not possible; and 
viable strains can only be created with single-copy integration (Hodgkin, 2005). I 
favor the use creating integrated, single-copy transgenic strains to examine 
overexpression phenotypes of both pdxk-1 and mtq-2 in the future. Regrettably, 
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creating integrated, single-copy transgenic strains is not a high-throughput 
technique; yet, the initial investment of labor can instill greater confidence in any 
results garnered from such studies.  
Finally, it is my sincere hope that Down syndrome researchers employing 
mouse models can further examine the candidate genes I identified. There are 
two gold standard experiments that could be performed. First, transgenic mice 
overexpressing a single candidate gene could be generated and phenotypically 
characterized. Positive results from this experiment would indicate if 
overexpression of a candidate gene at physiologically relevant levels is sufficient 
to confer a phenotype. In mouse, transgenic overexpression of a wild-type 
HSA21-related gene can cause abnormal neurological phenotypes. For instance, 
overexpression of synaptojanin, Synj1, causes subtle spatial memory defects, 
while overexpression of Dyrk1a causes severe spatial memory defects, learning 
difficulties and altered synaptic plasticity (Ahn et al., 2006; Altafaj et al., 2001; 
Kleschevnikov et al., 2004; Voronov et al., 2008). Second, a candidate gene could 
be restored to disomic levels within a Down syndrome mouse model. Restoring a 
single gene to disomic levels on a Down syndrome mouse background can most 
readily be executed by a simple genetic cross; however, this does require 
haplosufficiency of the gene of interest. Results from these experiments can 
indicate the function of a given gene within the context of Down syndrome. 
 
Future Directions for MTQ-2 
In further characterizing a novel candidate gene that emerged from my 
screen, I found that mtq-2 is required for normal nervous system function, 
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normal excitatory neurotransmission, and that it functions, specifically, in 
cholinergic neurons to mediate its effects. Initial genetic epistasis analysis 
suggests mtq-2 may function upstream of or in conjunction with at least one Gα 
signaling protein, GαO. These results are intriguing, and, I believe, sufficient to 
justify closer examination of mtq-2 in mammals. Though mice homozygous null 
for mtq-2 (N6Amt1) die very in embryonic development, the consequences of 
overexpression of this gene in mice are unknown (P. Liu et al., 2010).   
There are still many unanswered questions regarding the mechanism of 
action of mtq-2. Critically, biochemical experiments are needed to determine the 
following: 1) What does MTQ-2 bind in worm? 2) Is the protein methylome 
altered in an mtq-2 background, or more feasibly 3) Is goa-1 (GαO) methylated at 
glutamine? If so, 4) is mtq-2 required for this modification? Positive results from 
the latter two questions would suggest a remarkable level of fine tuning of a key 
synaptic protein and suggest a functional role for non-histone glutamine 
methylation, a scarcely described post-translational modification. 
If the aforementioned biochemical experiments do not support an 
interaction between goa-1 (GαO) and mtq-2, then alternate possibilities must be 
considered. In both yeast and mouse, MTQ-2 has been shown to partner with an 
adaptor subunit, TRM112. Though the gene (C04H5.1) encoding the adaptor 
subunit is well-conserved in worm, it has no known deletion or loss-of-function 
alleles and we did not pursue it. In yeast, both Liger and Figaro found that 
TRM112 functioned as a hub protein within a small network of genes including 
two tRNA methyltransferases, the protein methyltransferase, mtq-2, and an 
rRNA methyltransferase (Figure 4.2) (Figaro et al., 2012; Liger et al., 2011). Figaro 
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hypothesized that disrupting the levels of any of the catalytic subunits could 
perturb the function of the others by disrupting the normal stoichiometry of 
subunits in the methyltransferase complex. In worm, all of the genes in this small 
network are conserved but uncharacterized. Curiously, of those genes with 
known expression patterns, C35D10.12 (TRM9) and Y71F9AL.1 (TRM11) appear 
quite similar to the expression pattern I found for mtq-2. This raises the 
possibility that they may work together for some common purpose in the 
nervous system (Figure 4.2). Again, biochemical assays would help expedite an 
understanding of the interacting partners of mtq-2.  
Finally, mtq-2 may have an unappreciated role in development. Regarding 
nervous system development, I examined the localization, distribution, and 
relative fluorescence intensity of cholinergic synapses in the DA9 neuron and did 
not find major differences between wild-type animals and mtq-2 mutants (Figure 
3.5). However, both mtq-2 mutants and strains overexpressing mtq-2 exhibited 
several other phenotypes suggestive of developmental deficits. First, I 
consistently noted that mtq-2 mutants were slightly delayed (~8 hours) in 
reaching a distinctive larval stage (L4). The delay in reaching the L4 stage may be 
due to general growth deficits or to eggs being laid at a premature stage. Future 
experiments dissecting the stage of eggs in utero in mtq-2 mutants could support 
or controvert the latter possibility. Second, I found that overexpression of mtq-2 
in a wild-type background under its endogenous promoter caused pronounced 
sterility (Figure 4.3), which was possibly dose-dependent. Like growth delay, 
sterility can be caused by many factors, and it is not clear from my work why 
overexpression of mtq-2 resulted in sterility. Interestingly, reduction in function 
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of one of the candidate interacting partners of mtq-2 that I identified, goa-1 (GαO), 
is also associated with developmental defects, including sterility (Miller & Rand, 
2000).   
 
Final Remarks 
For decades, functional analysis of 21st chromosome genes has been a priority 
within the field of Down syndrome research. Ignorance of the in vivo function of 
genes on the 21st chromosome, hobbles efforts to fully understand the genetic 
basis of the disorder. The research I conducted in this thesis is a step forward. 
Importantly, over half of the genes I identified in my systematic screen of 21st 
chromosome orthologs are inviable in mice, which may explain why some of 
them had been overlooked. To truly appreciate Down syndrome, it is imperative 
for researchers to rely on multiple approaches and multiple animal models. 
Discoveries in invertebrates may not always translate to mammals, but the return 
is immense when they do. 
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Human Gene Worm Gene Function Expression 
ATP5O atp-3 ATP synthase subunit nervous system1, 2 
CCT8 cct-8 chaperonin subunit - 
CHAF1B chaf-2 chromatin assembly factor - 
HSPA13 stc-1 ATPase intestine1, 2 
MRPL39 mrpl-39 mitochondrial ribosomal protein - 
MRPS6 mrps-6 mitochondrial ribosomal protein - 
UBE2G2 ubc-14 ubiquitin conjugating enzyme nervous system1, 2 
WDR4 wdr-4 WD Repeat protein - 
 
 
Table 4.1. Well-conserved orthologs of HSA21 genes inviable in C. elegans 
List of human genes, corresponding worm gene, function of gene in worm, and 
in which tissue the gene expresses (if known). – indicates unknown expression 
pattern. Data for expression pattern was gathered from WormBase (Lee et al., 
2018). Specific citations are as follows: 1(McKay et al., 2003) and 2(Hunt-Newbury 
et al., 2007).  
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Figure 4.1. Alignment of PDXK and location of missense mutations  
Human and C. elegans PDXK were aligned with Clustal Omega. Shading 
indicates residues affected by mutations in the Million Mutation Project (MMP). 
Gray shading indicates missense mutations in residues not conserved. Strains 
harboring mutations affecting residues shaded in blue were screened (VC20794, 
M271I and VC40336, T155I). Strain (VC40866) harboring E148K mutation red was 
screened and found to have behavioral and synaptic defects. 
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Figure 4.2. Partners and predicted partners of hub protein TRM112   
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Figure 4.2. Partners and predicted partners of hub protein TRM112   
A. Schematic illustrating the four catalytic subunits known to associate with the 
hub protein, TRM112 in yeast. Model derived from (Figaro et al., 2012; Liger et 
al., 2011). Orthology was determined with InParanoid. Black text refers to the 
gene name S. cerevisiae; blue, C. elegans; and red, H. sapiens. B. Images of 
transcriptional reporters of C.elegans genes predicted, by homology, to 
participate in network. Asterisk indicates location of vulva. Images for 
C35D10.12 (TRM9) and Y71F9AL.1 (TRM11) were taken from the C.elegans 
Promoter Expression Database. For images of mtq-2 see (Nordquist et al., 2018). 
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Figure 4.3. Overexpression of mtq-2 causes sterility 
Shown here is the mean percent sterile at day four of adulthood. At least 20 
animals per strain tested. Significance ( *p < 0.05, ***p < 0.001) determined with 
Fischer's exact test. 0 indicates no sterility. 
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APPENDIX A. LIST OF HSA21 ORTHOLOGS SELECTED FOR STUDY 
 
#Human 
Gene 
Human 
Uniprot 
Human 
Gene 
Mouse 
Gene DSCR Ts65Dn 
Worm 
Uniprot 
Worm 
Gene 
#Worm 
Gene 
1 P78563 ADARB1 Adarb1 
  
Q22618 adr-2 1 
2 P48047 ATP5O Atp5o 
 
✓ Q7JNG1 atp-3 2 
3 Q9Y2C3 B3GALT5 B3galt5 ✓ ✓ Q8MQG4 B0024.15 3 
4 P35520 CBS Cbs 
  
Q93244 cysl-1 4 
 
P35520 CBS Cbs 
  
O45679 cysl-2 5 
 
P35520 CBS Cbs 
  
O01592 cysl-3 6 
 
P35520 CBS Cbs 
  
O16284 cysl-4 7 
5 P50990 CCT8 Cct8 
 
✓ Q9N358 cct-8 8 
6 Q13112 CHAF1B Chaf1b ✓ ✓ Q95XL8 chaf-2 9 
7 Q96NY7 CLIC6 Clic6 
 
✓ G5ED64 D1086.9 10 
 
Q96NY7 CLIC6 Clic6 
 
✓ Q564Q6 H39E23.3 11 
8 P39060 COL18A1 Col18a1 
  
G5EGA4 cle-1 12 
9 Q14689 DIP2A Dip2a 
  
Q1RS87 dip-2 13 
10 Q9NYP3 DONSON Donson 
 
✓ H2KYF1 dnsn-1 14 
11 Q9Y3R5 DOPEY2 Dopey2 ✓ ✓ Q9XW10 pad-1 15 
12 O60469 DSCAM Dscam ✓ ✓ Q9TXI8 igcm-1 16 
13 Q13627 DYRK1A Dyrk1a ✓ ✓ Q8WQL7 mbk-1 17 
14 P58658 EVA1C Eva1c 
 
✓ Q9XU98 eva-1 18 
15 P22102 GART Gart 
 
✓ Q20143 F38B6.4 19 
16 P48723 HSPA13 Hspa13 
  
Q20752 stc-1 20 
17 P05107 ITGB2 Itgb2 
  
Q27874 pat-3 21 
18 Q15811 ITSN1 Itsn1 
 
✓ Q9U2T9 itsn-1 22 
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19 P57087 JAM2 Jam2 
 
✓ A8WFH3 zig-10 23 
20 P48051 KCNJ6 Kcnj6 ✓ ✓ D3YT08 irk-2 24 
21 O94822 LTN1 Ltn1 
 
✓ Q65XX2 Y54E10A.11 25 
22 Q9NYK5 MRPL39 Mrpl39 
 
✓ Q4W5T0 mrpl-39 26 
23 P82932 MRPS6 Mrps6 
 
✓ O61791 mrps-6 27 
24 Q9Y5N5 N6AMT1 N6amt1 
 
✓ O16582 mtq-2 28 
25 O15394 NCAM2 Ncam2 
  
Q8MQ86 ncam-1 29 
26 Q9Y5B6 PAXBP1 Paxbp1 
 
✓ G5ECH1 F43G9.12 30 
27 P57721 PCBP3 Pcbp3 
  
Q95Y67 pes-4 31 
28 O00764 PDXK Pdxk 
  
O01824 pdxk-1 32 
29 P17858 PFKL Pfkl 
  
Q9TZL8 pfk-1.1 33 
30 Q9Y2G5 POFUT2 Pofut2 
  
Q8WR51 pad-2 34 
31 Q86YR6 POTED Poteg 
  
G5EFS1 ikb-1 35 
32 P53805 RCAN1 Rcan1 
 
✓ P53806 rcan-1 36 
33 P56182 RRP1 Rrp1 
  
Q18674 C47E12.7 37 
34 Q14684 RRP1B Rrp1b 
  
Q18674 C47E12.7 dup. 
35 Q01196 RUNX1 Runx1 
 
✓ G5EFQ5 rnt-1 38 
36 O95104 SCAF4 Scaf4 
 
✓ O01864 nrd-1 39 
37 Q9NVD3 SETD4 Setd4 ✓ ✓ Q9BPP1 set-29 40 
38 P55822 SH3BGR Sh3bgr ✓ ✓ K8ES47 Y105E8A.1 41 
39 Q14190 SIM2 Sim2 ✓ ✓ P90953 hlh-34 42 
40 P00441 SOD1 Sod1 
 
✓ 
 
sod-1 43 
 
P00441 SOD1 Sod1 
 
✓ 
 
sod-5 44 
41 P18583 SON Son 
 
✓ Q9TYS1 D1037.1 45 
42 O43426 SYNJ1 Synj1 
 
✓ G5ECL2 unc-26 46 
43 P56557 TMEM50B Tmem50b 
 
✓ Q9N2X7 Y74C10AL.2 47 
44 P48553 TRAPPC10 Trappc10 
  
B1V899 trpp-10 48 
45 P60604 UBE2G2 Ube2g2 
  
Q9U1Q1 ubc-14 49 
APPENDIX A 
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46 Q9UHP3 USP25 Usp25 
  
Q09931 K02C4.3 50 
47 P57081 WDR4 Wdr4 
  
Q23232 wdr-4 51 
 
 
APPENDIX A. LIST OF HSA21 ORTHOLOGS SELECTED FOR STUDY 
List of 47 human genes on 21st chromosome with one or more C. elegans 
orthologs predicted by the InParanoid algorithm. Because the 47 human genes 
are represented by 51 genes in C. elegans, several human genes are matched to 
multiple worm genes. For instance, the human gene CBS is matched to worm 
genes: cysl-1, cysl-2, cysl-3, and cysl-4.  In only one case two paralogous human 
genes (RRP1 and RRP1B) are matched to a single worm gene in (C47E12.7), 
indicated by the text “dup.” for duplicate. Of the 47 human genes, 19 are 
matched one-to-one with worm gene (bold), 25 are matched many-to-one with 
(25) worm genes, and 3 are matched one-to-many (8) worm genes. In total, the 47 
human genes are represented by 51 unique orthologs in C. elegans. To 
demonstrate this relation, unique human and worm genes are numbered on left 
and right sides. Columns list corresponding Uniprot ID for human gene, mouse 
orthologous gene, whether the gene has been reported to lie within the so-called 
Down syndrome critical region (DSCR) ((X. Jiang et al., 2015), whether the 
corresponding mouse gene is overexpressed in the common mouse model of 
Down syndrome Ts65Dn ((Olson et al., 2004), the worm Uniprot identification 
code, and worm gene name. 
 
  
 104 
APPENDIX B. COVERAGE AND REPLICATION OF RNAI SCREEN OF 
HSA21 ORTHOLOGS SELECTED FOR SCREEN 
 
Human 
Gene 
Worm 
Gene 
RNAi 
Probe 
Not 
Viable 
Not 
Viable 
Replicated WT 
WT 
Replicated Conflict 
ADARB1 adr-2 III-3J14 
  
✓ ✓ 
 
ATP5O atp-3 I-2O16 ✓ ✓ 
   
B3GALT5 B0024.15 V-7K15 
  
✓ 
  
CBS cysl-1 X-4L22 
  
✓ ✓ 
 
CBS cysl-2 II-9M07 
  
✓ ✓ 
 
CBS cysl-3 V-3C18 
  
✓ ✓ 
 
CBS cysl-4 V-2A09 
  
✓ 
  
CCT8 cct-8 IV-8P07 ✓ ✓ 
   
CHAF1B chaf-2 I-8O03 
  
✓ 
 
✓ 
CLIC6 D1086.9 - 
     
CLIC6 H39E23.3 - 
     
COL18A1 cle-1 I-4E22 
  
✓ ✓ 
 
DIP2A dip-2 I-2M19 ✓ ✓ 
   
DONSON dnsn-1 II-1O15 ✓ ✓ 
   
DOPEY2 pad-1 I-6F05 ✓ ✓ 
   
DSCAM igcm-1 X-8D03 
  
✓ 
  
DYRK1A mbk-1 X-6J16 
  
✓ ✓ 
 
EVA1C eva-1 I-7I22 
  
✓ ✓ 
 
GART F38B6.4 X-3F13 
  
✓ ✓ 
 
HSPA13 stc-1 II-6A08 ✓ ✓ 
   
ITGB2 pat-3 III-1P02 ✓ ✓ 
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ITSN1 itsn-1 IV-8I23 
  
✓ ✓ 
 
JAM2 zig-10 II-5A05 
  
✓ ✓ 
 
KCNJ6 irk-2 X-1I21 
  
✓ 
 
✓ 
LTN1 Y54E10A.11 - 
     
MRPL39 mrpl-39 V-1L20 ✓ ✓ 
   
MRPS6 mrps-6 I-1H04 ✓ ✓ 
   
N6AMT1 mtq-2 II-2M20 
  
✓ ✓ 
 
NCAM2 ncam-1 X-1I17 
  
✓ ✓ 
 
PAXBP1 F43G9.12 I-4C12 ✓ ✓ 
   
PCBP3 pes-4 III-8I07 ✓ ✓ 
   
PDXK pdxk-1 I-2K05 
  
✓ ✓ 
 
PFKL pfk-1.1 X-2C11 ✓ ✓ 
   
POFUT2 pad-2 
III-
8G24 
  
✓ ✓ 
 
POTED ikb-1 I-4H10 
  
✓ ✓ 
 
RCAN1 rcan-1 III-3A09 
  
✓ ✓ 
 
RRP1 C47E12.7 IV-5O03 ✓ ✓ 
   
RRP1B C47E12.7 dup. dup. dup. 
   
RUNX1 rnt-1 I-2L23 
  
✓ ✓ 
 
SCAF4 nrd-1 I-2A21 ✓ ✓ 
   
SETD4 set-29 - 
     
SH3BGR Y105E8A.1 I-9O01 
  
✓ 
  
SIM2 hlh-34 V-9C07 
  
✓ ✓ 
 
SOD1 sod-1 II-5G04 
  
✓ 
  
SOD1 sod-5 II-3F14 
  
✓ ✓ 
 
SON D1037.1 I-1F05 
  
✓ ✓ 
 
SYNJ1 unc-26 IV-7E19 
  
✓ ✓ 
 
TMEM50B Y74C10AL.2 - 
     
APPENDIX B. 
 106 
TRAPPC10 trpp-10 I-9P01 
  
✓ ✓ 
 
UBE2G2 ubc-14 - 
     
USP25 K02C4.3 II-5P18 
  
✓ ✓ 
 
WDR4 wdr-4 III-3F21 
  
✓ ✓ 
  
 
APPENDIX B. COVERAGE AND REPLICATION OF RNAI SCREEN OF 
HSA21 ORTHOLOGS SELECTED FOR SCREEN 
Display of the degree of coverage and replication for our RNAi analysis. We list 
46 RNAi probes from the Ahringer library used for phenotypic testing. Only 6 
HSA21 orthologs did not have a corresponding RNAi clone. Checkmarks 
indicate phenotypes we found that may preclude study of these genes in loss-of-
function mutations including embryonic lethal (Emb), sterile (Ste), severe growth 
defect (Gro), and larval arrest (Lva). ((Ceron et al., 2007; Cui et al., 2008; A. G. 
Fraser et al., 2000; Gottschalk et al., 2005; Jones, Crowe, Stevens, & Candido, 
2002; Kamath et al., 2003; Maeda et al., 2001; Nakano et al., 2011; Pujol et al., 2001; 
Rual et al., 2004; Simmer et al., 2003; Sönnichsen et al., 2005). 
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APPENDIX C. COVERAGE AND REPLICATION OF MUTANT SCREEN OF 
HSA21 ORTHOLOGS SELECTED FOR STUDY 
 
Human 
Gene 
Worm 
Gene Strain 
Tested or 
Not Viable Pheno. 
1st 
Report 
Pheno. 
Rep. Conflict 
ADARB1 adr-2 BB3 ✓ 
    
ATP5O atp-3 - ✓ 
    
B3GALT5 B0024.15 FX6706 ✓ 
    
CBS cysl-1 RB899 ✓ 
    
CBS cysl-2 RB2535 ✓ ✓ ✓ 
  
CBS cysl-3 - 
     
CBS cysl-4 RB2436 ✓ 
    
CCT8 cct-8 - ✓ 
    
CHAF1B chaf-2 - ✓ 
    
CLIC6 D1086.9 - 
     
CLIC6 H39E23.3 - 
     
COL18A1 cle-1 VC943 ✓ ✓ ✓ 
  
DIP2A dip-2 RB979 ✓ 
    
DONSON dnsn-1 FX3322 ✓ ✓ ✓ 
  
DOPEY2 pad-1 - ✓ 
    
DSCAM igcm-1 RB870 ✓ 
    
DYRK1A mbk-1 EK228 ✓ 
    
EVA1C eva-1 VC868 ✓ ✓ ✓ 
  
GART F38B6.4 - 
     
HSPA13 stc-1 - ✓ 
    
ITGB2 pat-3 - ✓ 
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ITSN1 itsn-1 VC201 ✓ 
    
JAM2 zig-10 FX6327 ✓ 
    
KCNJ6 irk-2 - ✓ 
    
LTN1 Y54E10A.11 - 
     
MRPL39 mrpl-39 - ✓ 
    
MRPS6 mrps-6 - ✓ 
    
N6AMT1 mtq-2 FX3565 ✓ ✓ ✓ 
  
NCAM2 ncam-1 VH860 ✓ ✓ ✓ 
  
PAXBP1 F43G9.12 - ✓ 
    
PCBP3 pes-4 - ✓ 
    
PDXK pdxk-1 VC40866 ✓ ✓ ✓ 
  
PFKL pfk-1.1 - ✓ 
    
POFUT2 pad-2 FX1756 ✓ ✓ ✓ 
  
POTED ikb-1 - 
     
RCAN1 rcan-1 FX2021 ✓ 
    
RRP1 C47E12.7 - ✓ 
    
RRP1B C47E12.7 - dup. 
    
RUNX1 rnt-1 VC200 ✓ ✓ ✓ 
  
SCAF4 nrd-1 FX2657 ✓ 
    
SETD4 set-29 RB2097 ✓ 
    
SH3BGR Y105E8A.1 FX2626 ✓ 
    
SIM2 hlh-34 - 
     
SOD1 sod-1 FX776 ✓ 
    
SOD1 sod-5 GA503 ✓ 
    
SON D1037.1 RB1489 ✓ 
    
SYNJ1 unc-26 DR97 ✓ ✓ 
 
✓ 
 
TMEM50B Y74C10AL.2 - 
     
TRAPPC10 trpp-10 - 
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UBE2G2 ubc-14 - ✓ 
    
USP25 K02C4.3 - ✓ 
    
WDR4 wdr-4 - ✓ 
    
 
 
APPENDIX C. COVERAGE AND REPLICATION OF MUTANT SCREEN OF 
HSA21 ORTHOLOGS SELECTED FOR STUDY  
Display of the degree of coverage and replication of our mutant analysis. We list 
the 30 outcrossed, homozygous viable strains with predicted loss-of-function 
mutations that we used to examine neuronal phenotypes in this study. There 
were also 12 orthologs for which RNAi or mutant data suggest inviability when 
mutated. Only 9 orthologs were not accounted for by a mutant or evidence of 
inviability. Mutant phenotypes detected in our study are listed. Only one of these 
genes (unc-26) had previously described mutant phenotypes (Harris et al., 2000). 
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APPENDIX D. OTHER PUTATIVE HSA21 ORTHOLOGS NOT SELECTED 
FOR SCREEN 
 
# Human 
gene 
Human 
Uniprot Human Gene Worm Gene # Worm gene 
1 P45844 ABCG1 wht-2 1 
 
P45844 ABCG1 wht-3 2 
 
P45844 ABCG1 wht-6 3 
 
P45844 ABCG1 wht-8 4 
 
P45844 ABCG1 wht-1 5 
 
P45844 ABCG1 wht-4 6 
 
P45844 ABCG1 wht-5 7 
 
P45844 ABCG1 wht-7 8 
2 Q9UHI8 ADAMTS1 gon-1 9 
3 Q9UNA0 ADAMTS5 gon-1 
 
4 P05067 APP apl-1 10 
- Q9Y2C3 B3GALT5 bre-2 11 
 
Q9Y2C3 B3GALT5 C47F8.3 12 
 
Q9Y2C3 B3GALT5 C47F8.5 13 
 
Q9Y2C3 B3GALT5 C47F8.6 14 
 
Q9Y2C3 B3GALT5 C54C8.3 15 
 
Q9Y2C3 B3GALT5 E03H4.11 16 
 
Q9Y2C3 B3GALT5 F14B6.4 17 
 
Q9Y2C3 B3GALT5 F14B6.6 18 
 
Q9Y2C3 B3GALT5 T09E11.10 19 
 
Q9Y2C3 B3GALT5 T09F5.1 20 
 
Q9Y2C3 B3GALT5 T15D6.5 21 
5 Q9Y5Z0 BACE2 asp-1 22 
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Q9Y5Z0 BACE2 asp-2 23 
 
Q9Y5Z0 BACE2 asp-5 24 
 
Q9Y5Z0 BACE2 asp-6 25 
 
Q9Y5Z0 BACE2 C11D2.2 26 
 
Q9Y5Z0 BACE2 C15C8.3 27 
 
Q9Y5Z0 BACE2 F21F8.2 28 
 
Q9Y5Z0 BACE2 F21F8.4 29 
 
Q9Y5Z0 BACE2 F28A12.4 30 
 
Q9Y5Z0 BACE2 F59D6.2 31 
 
Q9Y5Z0 BACE2 F59D6.3 32 
 
Q9Y5Z0 BACE2 K10C2.3 33 
 
Q9Y5Z0 BACE2 Y39B6A.22 34 
 
Q9Y5Z0 BACE2 Y39B6A.23 35 
 
Q9Y5Z0 BACE2 Y39B6A.24 36 
 
Q9Y5Z0 BACE2 ZK384.3 37 
 
Q9Y5Z0 BACE2 ZK384.6 38 
6 O43822 C21orf2 F09G8.5 39 
7 Q9Y426 C2CD2 R11G1.6 40 
8 P16152 CBR1 dhs-31 41 
9 O75828 CBR3 dhs-31 
 
- P35520 CBS cbs-1 42 
 
P35520 CBS cbs-2 43 
 
P35520 CBS F59A7.7 44 
- Q96NY7 CLIC6 exc-4 45 
 
Q96NY7 CLIC6 exl-1 46 
10 P12109 COL6A1 C16E9.1 47 
 
P12109 COL6A1 C18H7.1 48 
 
P12109 COL6A1 cutl-23 49 
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11 P12110 COL6A2 C16E9.1 50 
 
P12110 COL6A2 C18H7.1 51 
 
P12110 COL6A2 cutl-23 52 
12 P02489 CRYAA hsp-12.1 53 
 
P02489 CRYAA hsp-12.2 54 
 
P02489 CRYAA hsp-12.3 55 
 
P02489 CRYAA hsp-12.6 56 
13 P11308 ERG ast-1 57 
 
P11308 ERG ets-5 58 
14 P15036 ETS2 ets-7 59 
 
P15036 ETS2 ets-9 60 
 
P15036 ETS2 F19F10.1 61 
15 P58499 FAM3B M70.4 62 
 
P58499 FAM3B Y73B3A.3 63 
16 Q06546 GABPA ets-7 64 
 
Q06546 GABPA F19F10.1 65 
17 P39086 GRIK1 glr-3 66 
 
P39086 GRIK1 glr-4 67 
 
P39086 GRIK1 glr-5 68 
 
P39086 GRIK1 glr-1 69 
 
P39086 GRIK1 glr-2 70 
18 P50747 HLCS bpl-1 71 
19 Q99712 KCNJ15 irk-3 72 
20 O60318 MCM3AP F20D12.2 73 
21 Q14149 MORC3 morc-1 74 
- Q9NYK5 MRPL39 tars-1 75 
22 P20591 MX1 dyn-1 76 
23 P20592 MX2 dyn-1 
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24 Q8TAK6 OLIG1 hlh-16 77 
25 Q13516 OLIG2 hlh-16 
 
26 O95613 PCNT lfi-1 78 
- P17858 PFKL pfk-1.2 79 
- Q86YR6 POTED act-1 80 
 
Q86YR6 POTED act-2 81 
 
Q86YR6 POTED act-3 82 
 
Q86YR6 POTED act-4 83 
 
Q86YR6 POTED act-5 84 
27 P53801 PTTG1IP C37C3.12 85 
28 Q15269 PWP2 F55F8.3 86 
29 P57052 RBM11 Y37D8A.21 87 
30 P41440 SLC19A1 folt-1 88 
 
P41440 SLC19A1 folt-2 89 
 
P41440 SLC19A1 folt-3 90 
31 P57057 SLC37A1 T10C6.6 91 
 
P57057 SLC37A1 T11G6.2 92 
 
P57057 SLC37A1 T11G6.3 93 
 
P57057 SLC37A1 T11G6.4 94 
- P00441 SOD1 sod-4 95 
- P18583 SON C04G2.8 96 
 
P18583 SON C10G11.9 97 
 
P18583 SON T27A3.4 98 
32 P55854 SUMO3 smo-1 99 
33 Q13009 TIAM1 cgef-2 100 
34 O94759 TRPM2 ced-11 101 
35 P53804 TTC3 C09E7.7 102 
 
P53804 TTC3 C09E7.8 103 
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P53804 TTC3 C09E7.9 104 
 
P53804 TTC3 F27B3.5 105 
36 Q01081 U2AF1 uaf-2 106 
37 P57075 UBASH3A F09C12.8 107 
 
P57075 UBASH3A F55A11.11 108 
 
P57075 UBASH3A T07F12.1 109 
- P60604 UBE2G2 ubc-7 110 
38 O60287 URB1 T05H4.10 111 
 
APPENDIX D. OTHER PUTATIVE HSA21 ORTHOLOGS NOT SELECTED 
FOR SCREEN 
List of human 21st chromosome genes with one or more ortholog predicted by 
OrthoList but not InParanoid. There are 38 unique human genes (indicated with 
a number) in this category. The remaining 8 unique human genes (indicated with 
a dash) have an InParanoid defined ortholog listed in APPENDIX B. Because the 
46 human genes are represented by 111 genes in C. elegans, most human genes 
are matched to multiple worm genes. e.g. The human gene ABCG1 is matched to 
four paralogs: wht-2, wht-3, wht-6, and wht-8.  In four cases, paralogous human 
genes are matched to the same worm gene. e.g. OLIG1 and OLIG2 are both 
matched to hlh-16 in worm. 
  
 115 
APPENDIX E. ALPHABETICAL LIST OF HSA21 GENES WITH NO 
ORTHOLOG 
 
# Human 
Gene 
Human 
Gene 
# Human 
Gene 
Human 
Gene 
# Human 
Gene 
Human 
Gene 
# Human 
Gene 
Human 
Gene 
1 AGPAT3 33 IFNAR1 65 KRTAP19-4 97 PCP4 
2 AIRE 34 IFNAR2 66 KRTAP19-5 98 PDE9A 
3 ATP5J 35 IFNGR2 67 KRTAP19-6 99 PIGP 
4 BACH1 36 IGSF5 68 KRTAP19-7 100 PKNOX1 
5 BAGE3 37 IL10RB 69 KRTAP19-8 101 PLAC4 
6 BAGE4 38 KCNE1 70 KRTAP20-1 102 PRDM15 
7 BRWD1 39 KCNE2 71 KRTAP20-2 103 PRMT2 
8 BTG3 40 KRTAP10-1 72 KRTAP20-3 104 PSMG1 
9 C21orf140 41 KRTAP10-10 73 KRTAP21-1 105 RIPK4 
10 C21orf33 42 KRTAP10-11 74 KRTAP21-2 106 RIPPLY3 
11 C21orf58 43 KRTAP10-12 75 KRTAP21-3 107 RSPH1 
12 C21orf59 44 KRTAP10-2 76 KRTAP22-1 108 RWDD2B 
13 C21orf62 45 KRTAP10-3 77 KRTAP22-2 109 S100B 
14 C21orf91 46 KRTAP10-4 78 KRTAP23-1 110 SAMSN1 
15 CHODL 47 KRTAP10-5 79 KRTAP24-1 111 SIK1 
16 CLDN14 48 KRTAP10-6 80 KRTAP25-1 112 SLC5A3 
17 CLDN17 49 KRTAP10-7 81 KRTAP26-1 113 SMIM11 
18 CLDN8 50 KRTAP10-8 82 KRTAP27-1 114 SPATC1L 
19 CRYZL1 51 KRTAP10-9 83 KRTAP6-1 115 TCP10L 
20 CSTB 52 KRTAP11-1 84 KRTAP6-2 116 TFF1 
21 CXADR 53 KRTAP12-1 85 KRTAP6-3 117 TFF2 
22 CYYR1 54 KRTAP12-2 86 KRTAP7-1 118 TFF3 
23 DNAJC28 55 KRTAP12-3 87 KRTAP8-1 119 TMPRSS15 
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24 DNMT3L 56 KRTAP12-4 88 LCA5L 120 TMPRSS2 
25 DSCR3 57 KRTAP13-1 89 LIPI 121 TMPRSS3 
26 DSCR4 58 KRTAP13-2 90 LRRC3 122 TPTE 
27 FAM207A 59 KRTAP13-3 91 LSS 123 TSPEAR 
28 FTCD 60 KRTAP13-4 92 MAP3K7CL 124 UMODL1 
29 HMGN1 61 KRTAP15-1 93 MIS18A 125 USP16 
30 HSF2BP 62 KRTAP19-1 94 MRAP 126 WRB 
31 HUNK 63 KRTAP19-2 95 NDUFV3 127 YBEY 
32 ICOSLG 64 KRTAP19-3 96 NRIP1 128 ZBTB21 
 
APPENDIX E. ALPHABETICAL LIST OF HSA21 GENES WITH NO 
ORTHOLOG 
Alphabetical list of 128 human genes (HGNC name) on 21st chromosome with 
no predicted ortholog in C. elegans (determined by OrthoList). The 48 keratin 
genes are listed in bold. The remaining 80 genes are listed in regular font. 
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APPENDIX F. LIST OF OUTCROSSED MUTANT STRAINS 
 
Strain Gene Allele Chromosome Outcrossed # Parent Strain Source 
BB3 adr-2 gv42 III x 
 
CGC 
CB211 lev-1 e211 IV x 
 
CGC 
CZ18537 zig-10 tm6127 II x 
 
Y. Jin 
DR97 unc-26 e345 IV x 
 
CGC 
EK228 mbk-1 pk1389 X x 
 
CGC 
JPS641 pad-2 tm1756 III 3x FX1756 NBRP 
JPS686 rcan-1 tm2021 III 2x FX2021 NBRP 
JPS730 Y105E8A.1 tm2626 I 1x FX2626 NBRP 
JPS731 nrd-1 tm2657 I 1x FX2657 NBRP 
JPS636 dnsn-1 tm3322 II 3x FX3322 NBRP 
JPS637 mtq-2 tm3565 II 3x FX3565 NBRP 
JPS684 B0024.15 tm6706 V 1x FX6706 NBRP 
FX776 sod-1 tm776 II x 
 
NBRP 
GA503 sod-5 tm1146 II x 
 
NBRP 
MT1072 egl-4 n477 IV x 
 
CGC 
N2 
     
CGC 
JPS689 ikb-1 nr2027 I 3x NS3026 CGC 
PR678 tax-4 p678 III x 
 
CGC 
PS2627 dgk-1 sy428 X x 
 
CGC 
JPS693 D1037.1 ok1746 I 1x RB1489 CGC 
JPS642 set-29 ok2772 I 3x RB2097 CGC 
JPS980 cysl-4 ok3359 V 3x RB2436 CGC 
RB2535 cysl-2 ok3516 II x 
 
CGC 
JPS687 igcm-1 ok711 X 2x RB870 CGC 
JPS639 cysl-1 ok762 X 2x RB899 CGC 
 118 
JPS685 dip-2 ok885 I 1x RB979 CGC 
JPS690 rnt-1 ok351 I 1x VC200 CGC 
JPS683 itsn-1 ok268 IV 2x VC201 CGC 
JPS694 mtq-2 ok3740 II 2x VC3037 CGC 
JPS966 pdxk-1 gk855208 I 3x VC40866 CGC 
VC868 eva-1 ok1133 I x 
 
CGC 
JPS638 cle-1 gk421 I 1x VC943 CGC 
VH860 ncam-1 hd49 X x 
 
H. Hutter 
 
 
APPENDIX F. LIST OF OUTCROSSED MUTANT STRAINS 
List of all outcrossed strains used in study, genotype, number of times 
outcrossed, parent strain from which outcrossed strain was derived, and the 
source of the strain. A single x indicates that the strain has been outcrossed an 
indeterminate number of times by outside laboratories. CGC, Caenorhabditis 
Genetics Center. NBRP, National BioResource Project.  
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